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Colorectal cancer and KRAS
Colorectal cancer (CRC) is the second most common tumor type worldwide and accounts for 
more than 5,000 cancer deaths each year in the Netherlands (www.cijfersoverkanker.nl). The 
KRAS gene has a key role in carcinogenesis, signal transduction and proliferation. Mutations 
in the KRAS gene are found in 40 percent of the CRC tumors. The most frequent mutations in 
KRAS are guanine to adenine transitions and guanine to thymine transversions with 90% of the 
somatic point mutations occurring in hotspot codon 12 (70%) or 13 (30%) in exon 1. Other, less 
frequent, mutations are found in codon 61, 62 and 146[1].
KRAS protein prenylation 
The activating KRAS mutation results in uncontrolled cell growth. To be active, the KRAS protein 
requires posttranslational prenylation, by binding to a farnesyl- (C-15) or geranylgeranylgroup 
(C-17). After prenylation KRAS becomes more hydrophobic and associates with the plasma 
membrane. Membrane association is crucial for the function of the KRAS protein in the RAS-
RAF-MAPK pathway. Inactivated KRAS is bound to GDP; activation occurs by the conversion 
of GDP to GTP by guanine exchange factors. The ratio of GDP and GTP is controlled by guanine 
exchange factors and GTPase-activating proteins (GAPs). Active KRAS is hydrolyzed by GAPs 
to return to an inactive state [2]. 
Figure 1: Overview of EGFR-dependent intracellular signaling. Abbreviations: AKT, protein kinase B; EGF, 
epidermal growth factor; EGFR, epidermal growth factor receptor; ERK, extracellular signal-related kinase; 
GRB2, growth factor bound protein 2; KRAS-GDP, KRAS bound to guanine diphosphate; KRAS-GTP, 
KRAS bound to guanine triphosphate; MEK, mitogen-activated protein kinase; MTOR, mammalian target 
of rapamycin; PI3K, phosphatidyl-inositide-3-kinase; PTEN, phosphatase and tensin homolog; RAF, V-raf 




EGFR antibodies cetuximab and panitumumab
Binding of a ligand to the Epidermal Growth Factor Receptor (EGFR) activates important 
downstream processes such as the RAS-RAF-MAPK and the PI3 kinase pathway (figure 1). The 
EGFR is an important target in the treatment of CRC. Blockage of the EGFR leads to inhibition of 
cancer cell growth. The two registered EGFR antibodies, cetuximab and panitumumab are both 
indicated for the treatment of metastatic CRC in RAS wild type patients only. In KRAS mutant 
patients, KRAS is permanently activated, leading to constant cell signaling and proliferation 
independent of the EGFR [3].
 
Figure 2: Overview of the mevalonate pathway and the inhibition of HMG-CoA by statins. Abbreviations: 
Acetyl-CoA (acetyl coenzyme A); EGFR, epidermal growth factor receptor; FTase, farnesyltransferase; 




Statins and colorectal cancer
Statins inhibit cholesterol synthesis via inhibition of HMG-CoA-reductase in the mevalonate 
pathway and also prevent protein prenylation (figure 2). We hypothesize that statins may be 
useful for modulating KRAS mutant tumors. It is well known that statins can be used to lower 
cholesterol and have shown to reduce the number of cardiovascular events and mortality in 
patients with cardiovascular risks [4]. In addition, the use of statins has been associated with a 
reduced risk in a variety of malignancies such as colon, rectum, lung and liver cancer [5]. To date, 
several studies and meta-analysis have investigated statin use and the risk of developing CRC 
and outcomes but with inconclusive findings[6-8]. Fewer studies focus on effects of statin after 
diagnosis during treatment [9-14].
Phenoconversion of KRAS to overcome EGFR antibody resistance
Statins may inhibit the expression of the mutant KRAS phenotype by preventing the prenylation 
of the KRAS protein and as a consequence preventing plasma membrane association and so 
inhibiting the overactivated KRAS protein. We theorised that the inhibitory effect of statins 
may normalise the phenotype into a more KRAS wild type phenotype and render KRAS mutant 
colorectal cancers sensitive to EGFR antibodies(5;6). 
FCGR3A and cetuximab
An important mechanism of action for some monoclonal antibodies, including cetuximab 
is antibody-dependent cellular cytotoxicity (ADCC). Monoclonal antibodies are generally 
molecules of the IgG class and have an antigen-binding fragment (Fab). Fc gamma receptors 
(FCGR) on effector cells, for example macrophages and natural killer cells, bind to the Fab 
fragment and this causes lysis of the cancer cell. Germline polymorphisms in the genes encoding 
the Fc gamma receptor 2A (FCGR2A) c.535A>G, resulting in a change of histidine to arginine 
at codon 131 and 3A (FCGR3A) c.818A>C resulting in a change of phenylalanine to valine at 
position 158 have been associated with decreased therapeutic activity of cetuximab[15].
Use of EGFR antibodies in patients with hepatic or renal impairment
Panitumumab and cetuximab are both used for the treatment of metastatic CRC, and a part 
of the patients will present with liver metastasis and subsequent hepatic impairment. On the 
other hand, some patients are heavily pre-treated with chemotherapy and radiotherapy and 
may have decreased renal function. This is especially the case in patients with head and neck 
cancer where cetuximab is being used in patients that cannot be treated with cisplatin, e.g. due 
to renal impairment. Knowledge on the dosing in these specials populations is highly relevant; 
nonetheless the pharmacokinetics and safety of both cetuximab and panitumumab are, to date, 




Aims and outline of this thesis
The general aims of this thesis with the common denominator ‘optimization of EGFR targeted 
monoclonal antibody therapy in cancer’ are to study:
1. The phenoconversion effects of statins on KRAS mutant colorectal cancer both in vitro and 
in CRC patient populations and their ability to render KRAS mutant colorectal cancer 
cells sensitive for the EGFR monoclonal antibodies cetuximab or panitumumab 
2. The effect of the germline polymorphisms in FCGR3A on cetuximab efficacy
3. The pharmacokinetics of the EGFR antibodies cetuximab and panitumumab in patients 
with renal or hepatic impairment 
In chapter 2 a systematic review is presented on clinical and preclinical studies with compounds, 
which interfere with the mevalonate pathway and the prenylation of KRAS, published before 
April 2009. The novel concept of modulation of the KRAS protein by altering the phenotype and 
the consequent sensitising for EGFR antibodies is discussed.
In chapter 3 the effects of the combined treatment with simvastatin and cetuximab are studied 
in vitro in different KRAS mutant and wild type cell lines. The sulforhodamine assay is used 
to study the effects of treatment on survival and proliferation. Upregulated and downregulated 
tyrosine and serine/threonine kinases and corresponding pathways influenced by concomitant 
treatment with simvastatin and cetuximab in KRAS mutant and KRAS wild type cell lines are 
explored. The aim of this study is to explore the responsible pathways which are affected by 
simvastatin and cetuximab treatment.
Our hypothesis is that KRAS mutant cetuximab treated patients with concurrent statin use 
may have a favourable outcome from EGFR therapy compared to non-users. Chapter 4 describes 
a retrospective evaluation of the effects of statin use in the CAIRO2 study cohort in KRAS 
mutant metastatic CRC patients treated with cetuximab. The primary objective in this study is to 
determine whether statin use during chemotherapy with CAPOX-bevacizumab and cetuximab 
is associated with improved progression free survival as compared to non-(statin) users.
In the RASTAT-C and RASTAT-P studies, described in chapter 5 and 6, treatment with 80 
mg simvastatin daily combined with panitumumab two-weekly or cetuximab weekly is studied 
in a Simon two stage design single arm clinical trials in patients with KRAS mutant CRC. The 
primary objective is to investigate whether the percentage of patients free from progression and 
alive 12.5 weeks after the first administration of cetuximab is similar to the results of the KRAS 
wild type population of phase III studies treated with cetuximab or panitumumab.
In the cetuximab arm of the CAIRO2 study the FCGR3A 818C (VF plus VV) allele was 
associated with decreased PFS in the entire group of KRAS mutant and wild type patients. The 
predictive role of this polymorphism may be independent of KRAS status. In chapter 7 these 
findings of FCGR3A status (in relation to KRAS status) on the progression free survival and 
overall survival in three cohorts of metastatic colorectal cancer patients treated are combined. In 
this meta-analysis individual patient data are pooled.
Many metastatic CRC patients will present with liver metastases and some with liver 
dysfunction. The pharmacokinetics of panitumumab in patients with hepatic impairment has 
not been investigated, and dosage adjustments are undetermined. Chapter 8 describes a case 
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of a patient with progressive metastatic CRC and liver dysfunction treated with panitumumab. 
Pharmacokinetic data and toxicity of this patient are compared to historical data from a 
population with adequate liver functions.
In the literature the effect of renal impairment on the pharmacokinetics of anticancer drugs 
are scarce. Chapter 9 reports a 68 year old metastatic osteosarcoma patient with impaired renal 
function due to prior chemotherapy, who was treated on compassionate use basis with 400 mg/
m2 cetuximab. Pharmacokinetic parameters are compared to pharmacokinetic data from a study 
population with normal kidney function.
This thesis ends with concluding remarks and future perspectives in chapter 10 and a 
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Colorectal cancer, KRAS, 
FCGR3A and statins
Chapter 2
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Therapeutic modulation of 




KRAS has an important role in colorectal carcinogenesis and mutant KRAS leads to a permanently 
activated KRAS protein. To exert its biological activity, KRAS requires post-translational modifi-
cation by prenylation.
KRAS modulation has become a promising concept for new therapies, mostly by interference 
with the mevalonate pathway and subsequently by the prenylation of KRAS. Clinical data of 
agents interfering with the mevalonate pathway and the prenylation of RAS are summarized and 
suggest that these agents might be effective when administered in combination with anticancer 
drugs that target KRAS. Here, we discuss the novel concept that modulation of KRAS might 
potentiate EGFR therapy by altering the KRAS phenotype.
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Therapeutic modulation of KRAS signaling in colorectal cancer
Introduction
Colorectal cancer (CRC) is the second most common tumor type in the USA and accounts for 
49,920 cancer deaths each year. It is, therefore, the second most common cause of cancer-related 
mortality in the USA, causing nearly 9% of all cancer-related deaths [1].
If diagnosed early, colorectal tumors can be cured by radical resection. Unfortunately, many 
patients are diagnosed with (distant) metastasis either during follow-up or at first presentation. A 
small subset of patients with metastasis confined to a single organ (mostly the liver) can be cured 
by resection. For the majority of patients with metastasized disease, however, the only treatment 
option is palliative systemic treatment. In the past decade, new chemotherapeutic agents for CRC 
have become available, such as irinotecan and oxaliplatin. For advanced or metastasized CRC 
patients failing 5-FU (or capecitabine or UFT (ftorafur plus uracil)), oxaliplatin and irinotecan, 
therapy with a monoclonal antibody against the epidermal growth factor receptor (EGFR) is 
advised, but only in patients with tumors not harboring an activating mutation in the KRAS 
gene. RAS has a key role in carcinogenesis, signal transduction and proliferation in colorectal 
carcinoma. Mutations in RAS are found in 30% of all cancers and are a potential target for 
therapy. This review focuses on the role of KRAS and the novel concept of modulating KRAS with 
statins, farnesyltransferase inhibitors, geranylgeranyltransferase inhibitors and bisphosponates 
in human colorectal carcinomas.
Search strategy
A systematic literature search in PubMed was conducted on 3 April 2009 using the following 
keywords and combinations: KRAS, (colorectal) carcinoma, farnesyltransferase inhibitors, 
geranylgeranyltransferase inhibitor, bisphosphonates, statins, EGFR inhibitors, cetuximab and 
panitumumab. Results were assessed by reviewing titles and abstracts, and relevant articles were 
retrieved. Cited references in these articles were used to find further relevant articles.
RAS proto-oncogenes
The RAS gene family consists of proto-oncogenes, which control cell growth in mammalian cells. 
Three different kinds of RAS oncogenes are known: Kirsten RAS (KRAS), Harvey RAS (HRAS) 
and Neuroblastoma RAS (NRAS); these members of the RAS gene family are closely related and 
function in a similar way [2]. The KRAS gene encodes for a 21 kDa membrane-bound guanosine 
triphosphate (GTP)/guanosine diphosphate (GDP)-binding G protein. The KRAS protein serves 
as a switch between the EGFR and the nucleus, controlling downstream processes. To be active, 
hydrophilic KRAS requires post-translational modification by prenylation. Ras terminates 
in a CAAX sequence: a cysteine (C), two aliphatic amino acids (A) and any amino acid (X). 
The CAAX sequence is subject to post-translational farnesylation or geranylgeranylation. A 
15-carbon chain from farnesylpyrophosphate (FPP) is added to the cysteine residue close to 
the carboxyl terminus, and this process is catalyzed by the enzyme farnesyl protein transferase 
(FTase). When FTase is inhibited, KRAS will be geranylgeranylated, thereby a 20-carbon chain 
of geranylgeranylpyrophosphate (GGPP) is added to ras catalyzed by geranylgeranyltransferase 
(GGTase) [3,4]. After isoprenylation of ras, the endopeptidase RCE1 protease removes the 
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AAX amino acids at the end of the carboxyl terminus. The new terminus is methylated by 
isoprenylcysteine carboxyl methyltranferase (ICMT) before RAS is transported to the cellular 
membrane. In NRAS and KRAS, the SH-group of cysteine residue is palmitoylated before 
transport to the membrane. As a consequence of post-translational modifications, KRAS 
becomes more hydrophobic and translocates from the cytosol to attach to the cell membrane 
by its farnesylgroup or geranylgeranylgroup [5–7] (figure 1). Membrane association of KRAS is 
crucial for its function in signaling and transforming activities.
Both FPP and GGPP are isoprenoids formed during the mevalonate pathway. FPP is a 
precursor for cholesterol, heme A, dolichols and ubiquinones, and GGPP can be formed out of 
FPP [8]. Inactivated KRAS is bound to GDP; activation occurs by the conversion of GDP to GTP 
by guanine exchange factors. In normal cells, the ratio of GDP and GTP is controlled by guanine 
exchange factors and GTPase-activating proteins (GAPs). Active KRAS is hydrolyzed by GAPs 
to return to an inactive state [9].
 
 
Figure 1: Post-translational modification of RAS. Abbreviations: F, farnesyl pyrophosphate; GG, geranyl-
geranylpyrophosphate; M, methylgroup; P, palmitoylgroup.
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KRAS signaling
KRAS is situated in the inner cell membrane. Binding of a ligand to the EGFR activates a 
downstream process to the nucleus. This process activates major pathways in the cell: the RAS–
RAF–mitogen-activated protein kinase (MAPK) and the PI3 kinase pathway (figure 2). KRAS 
has a key role in the RAS–RAF–MAPK pathway. Son of sevenless (SOS) is conformationally 
modificated by interaction with growth factor receptor bound protein 2. Activated SOS induces 
the KRAS pathway [10]. In RAS-RAF-MAPK signaling, KRAS activates serine–threonine kinase 
raf 1, which phosphorylates two MAPK kinases. These in turn phosphorylate other MAPKs. 
MAPKs translocate to the nucleus and activate transcription factors involved in proliferation 
[8,11]. Signaling via the PI3 kinase pathway activates AKT and thereby phosphoproteins, for 
example, p-GSK3 and p-AKT [12]. The tumor suppressor gene PTEN inhibits the PI3 kinase 
pathway.
Figure 2: Overview of EGFR-dependent intracellular signaling. Abbreviations: AKT, protein kinase B; EGF, 
epidermal growth factor; EGFR, epidermal growth factor receptor; ERK, extracellular signal-related kinase; 
GRB2, growth factor bound protein 2; KRAS-GDP, KRAS bound to guanine diphosphate; KRAS-GTP, 
KRAS bound to guanine triphosphate; MEK, mitogen-activated protein kinase; MTOR, mammalian target 
of rapamycin; PI3K, phosphatidyl-inositide-3-kinase; PTEN, phosphatase and tensin homolog; RAF, V-raf 
murine sarcoma viral oncogene homolog; SOS, son of sevenless.
KRAS mutations in cancer
KRAS mutations have an important role in tumorigenesis. In CRC, KRAS somatic mutations 
are thought to be involved in the transition of adenoma into carcinoma, contributing to tumor 
growth and atypia [13,14]. Mutant RAS is present in approximately 30% of all human cancers. 
KRAS mutational rate is high in some tumors; however, it is low in others (Table 1). Approximately 
40% of CRCs have mutations in KRAS.
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Table 1: Mutations of NRAS, KRAS and HRAS in different tumor types [32,93].
Tumor type RAS Frequency (%)
Colorectal carcinoma KRAS 50
Lung adenocarcinoma (NSCLC) KRAS 30
Pancreatic carcinoma KRAS 90
Melanoma NRAS 20
Thyroid carcinoma KRAS, NRAS, HRAS 50
Myeloid disorders NRAS (less frequently KRAS, HRAS) 30
Abbreviations: KRAS, Kirsten RAS gene; NSCLC, non-small cell lung carcinoma; NRAS, neuroblastoma 
RAS gene; HRAS, Harvey RAS.
Mutations are found in primary tumors and matched metastases. Most mutations are found in 
the primary tumor, indicating a role in early tumorigenesis. Mutations are occasionally found 
only in metastases; however, thus indicating such mutations can also occur during a later stage 
of disease [15].
The most frequent mutations in KRAS are guanine to adenine transitions and guanine to 
thymine transversions [16] with 90% of the somatic point mutations occurring in hotspot codon 
12 (70%) or 13 (30%) in exon 1. Other, less frequent, mutations are known in codon 61, 62 and 
146. The most frequent mutations in codon 12 and 13 are listed in Table 2. 6.6% of the somatic 
mutations are found outside codon 12 or 13 in codons 8, 9, 10, 15, 16, 19, 20 or 25[16]. A recent 
study showed mutations in codon 59, 61, 117 and 163 [17]. During tumor progression, more 
KRAS codon 12 mutations and fewer codon 13 mutations are found. In normal tissue, however, 
there is a balanced codons 12 and 13 mutation ratio [18].
 
Table 2: Common transitions and transversions in KRAS codon 12 and 13
Codon 12 mutations
GGT (glycine) → AGT (serine) G–A transition G12S
GGT (glycine) → GAT (aspartate) G–A transition G12D
GGT (glycine) → TGT (cysteine) G–T transversion G12C
GGT (glycine) → GTT (valine) G–T transversion G12V
GGT (glycine) → CGT (arginine) G–C transversion G12R
GGT (glycine) → GCT (alanine) G–C transversion G12A
Codon 13 mutations
GGC (glycine) → GAC (aspartate) G–A transition G13D
GGC (glycine) → TGC (cysteine) G–T transversion G13C
GGC (glycine) → GTC (valine) G–T transversion G13V
GGC (glycine) → CGC (arginine) G–C transversion G13R
GGC (glycine) → GCC (alanine) G–C transversion G13A
GGC (glycine) → AGC (serine) G–A transition G13S
Abbreviations: A, adenine; C, cytosine; G, guanine; T, thymine.
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Different mutations in codon 12 or 13 have various effects on disease progression [19]. Guanine 
to adenine point mutations are associated with methylguanine methyltransferase epigenetic 
silencing [20]. Mutations leading to a 12-glycine residue (without a side chain) toward a residue 
with a side chain interfere with the geometry of KRAS and the ability of GTP to be hydrolyzed 
to return to an inactive state. These mutations cause impaired GTPase activity: KRAS binds 
GAP, but there is no activation of the GAP because of steric hindrance [21], and they permit a 
permanently active state causing growth and proliferation [22,23]. Consequently, mutant KRAS 
operates independently of activation of the EGFR and causes downstream processes [24].
No clear conclusions can be drawn from the studies regarding the influence of KRAS on the 
progression of colon cancer and, thus, the prognostic impact of KRAS mutation in colorectal 
carcinoma is unclear. Several studies link KRAS to worse prognosis, whereas others do not 
implicate a prognostic role for KRAS [25–31]. The RASCAL study was initiated to determine 
whether the presence of KRAS mutations in CRC patients is associated with poor prognosis. 
Initial results of this study suggested that KRAS mutational status is indeed associated with 
poorer disease-free survival and overall survival. The RASCAL II study, however, reported that 
only one specific mutation reduces disease-free and overall survival statistically significant and 
that KRAS mutational status in general is not a prognostic marker. Nevertheless, mutational 
status of KRAS is of great clinical relevance in CRC patients in predicting response to EGFR-
inhibitor-based therapy. The RASCAL II study showed that only glycine to valine transversion 
on codon 12 had a statistically significant influence on interval between operation and relapse or 
death from any cause and on overall survival [19,32]. Post hoc analyses of two trials evaluating 
the EGFR inhibitors panitumumab and cetuximab in CRC showed lack of response to these 
agents in KRAS mutant patients [33,34]. Nowadays, EGFR inhibitor therapy in CRC is indicated 
only in patients free of mutations in codons 12 and 13 of the KRAS gene.
Testing for KRAS gene mutations
Currently, testing for KRAS mutations is not standardized. For the identification of KRAS 
mutations, different methods are being used; however, data about the accuracy of different tests 
are limited [12]. KRAS testing currently focuses on codon 12 or 13 mutations. Seven mutations 
in these codons contribute to more than 95% of all KRAS mutations. In real-time polymerase 
chain reactions, probes for the most common mutations in codons 12, 13 and sometimes 61 
are applied. In direct sequencing analysis, all possible mutations of KRAS can be identified [35]. 
Many methods of KRAS testing are laboratory-based methods. The following methods are used 
for KRAS testing: gel electrophoresis assays, sequencing, allele-specific PCR assays and allele-
discrimination-based allele-specific ligation detection reaction.
Allele discrimination is based on discrimination amplification efficiencies at low melting 
temperatures. Some assays are commercially available [36,37]. Juan et al. [38] compared testing 
methods (Histogenex, Genzyme, Invitek and Gentrix) from four independent commercial 
laboratories with their internal direct sequencing, and all but one (Invitek) were comparable 
with the internal direct sequencing method.
Tol et al. [36] compared two commonly used KRAS mutation tests, real time PCR and 
sequencing in DNA extracted from CRC samples. Both sequencing and real-time PCR are 
reliable KRAS testing assays with a sensitivity of 95.5% (95% confidence interval 91.7–97.9%) 
and 96.5% (95% confidence interval 93.0–98.6%), respectively.
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A difficulty in KRAS testing occurs when a low volume of tumor material is available, for example 
because of pre-treatment with radiotherapy. In samples with less than 30% tumor cells, a KRAS 
mutation can be missed by sequencing. Obviously, high-quality KRAS testing is necessary 
because the KRAS status of a patient is used to determine clinical opportunities. The European 
Society of Pathology has started a Quality Assessment program for KRAS testing because of the 
lack of procedures and standardization (http://esp-pathology.org).
KRAS and pathogenetic pathways in CRC
In the progression toward CRC, pathological genetic changes occur. This review focuses 
on KRAS; however, other genetic changes have an important role and interplay in colorectal 
carcinogenesis. Early genetic abnormalities arise in adenomatous polyposis coli, KRAS and 
BRAF (v-raf murine sarcoma viral oncogene homolog B1). Mismatch repair gene mutation and 
MLH1 mutation contribute to microsatellite instability. These pathological genetic changes lead 
to dysplastic crypt and (early) adenoma formation.
Further positive selection occurs for the mutation of TGFb receptor 2, insulin-like growth 
factor 2 receptor, BAX, loss of SMAD4, TP53 and PIK3CA, which lead to further progression to 
carcinoma.
 KRAS, BRAF, PTEN and PIK3CA are mediators of the down- stream signaling of the EGFR. 
Genetic alterations in these genes contribute to a different EGFR signaling. Oncogenic mutations 
in RAS and BRAF activate the MAPK signaling pathway. BRAF mutations occur in 13% of 
CRCs. PIK3CA encodes for PI3 kinase. PI3 kinase is controlled by PTEN, which could be lost 
in colorectal carcinoma. Figure 3 overviews the pathogenic changes and interplay in colorectal 
carcinoma [39,40].
Figure 3: Genetic alterations in colorectal carcinoma. Abbreviations: APC, adenomatous polyposis coli; 
BAX, BCL2-associated X protein; BRAF, V-raf murine sarcoma viral oncogene homolog; KRAS, Kirsten 
RAS gene; MMR, mismatch repair; MLH1, human mutL homolog 1; PIK3CA, phosphoinositide-3-kinase; 
catalytic, alpha polypeptide; PTEN, phosphatase and tensin homolog; SMAD4, SMAD family member 4; 
TGFBR2, transforming growth factor, beta receptor II; TP53, tumor protein p53.
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Targeting KRAS as an anticancer therapy
Modulating KRAS signaling has become a promising concept for new cancer therapies. A variety 
of approaches, mostly interfering with the mevalonate pathway, 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (HMG-CoA) reductase and prenylation of KRAS have been studied [41]. 
The mevalonate metabolites, FPP and GGPP, play an important part in the post-translational 
modification of KRAS and have become a target for different anticancer approaches. The effects 
of statins, bisphosphonates, FTIs, GGTIs, RAS converting enzyme 1 (Rce1) inhibitors and 
(soprenylcysteine carboxyl methyltransferase) ICMT inhibitors on the mevalonate pathway and 
indirectly on prenylation of KRAS (Fig. 4) and the results of phase I, II and III clinical studies 
are discussed.
Figure 4: Overview of the mevalonate pathway and inhibitors. The mevalonate pathway causes prenylation 
of ras, N-glycosylation of EGFR and membrane and steroid synthesis. Statins, bisphosphonates, 
farnesyltransferase inhibitors and geranylgeranyltransferase inhibitors have inhibitory effects on the 
mevalonate pathway and thus on prenylation of KRAS. Abbreviations: Acetyl-CoA (acetyl coenzyme A); 
EGFR, epidermal growth factor receptor; FTase, farnesyltransferase; FTIs, farnesyltransferase inhibitors; 
GGTase, geranylgeranyltransferase; GGTIs, geranylgeranyltransferase inhibitors; HMG-CoA (3-hydroxy-




Statins are HMG-CoA inhibitors, which suppress the cholesterol biosynthesis in humans by their 
inhibitory effect on the mevalonate pathway, thereby inhibiting the formation of low-density 
lipoprotein (LDL). Owing to upregulation of LDL receptors, the blood clearance of LDL also 
enhances, increasing the lipid-lowering effect of statins.
Besides the cholesterol-lowering effects, statins are believed to inhibit tumor cell growth and 
angiogenesis, induce apoptosis and impair tumor metastasis. Through inhibition of HMG-CoA, 
statins inhibit the formation of mevalonate, thereby affecting the synthesis of the isoprenoids 
FPP and GGPP. These substrates are used for farnesylation and geranylgeranylations of RAS 
and RHO. In addition, statins affect both angiogenesis and inflammation processes [5,42] and 
exert a role in chemoprevention by the inhibition of HMG-CoA reductase, which is upregulated 
in colon cancer cells [43]. In vitro studies have shown that statins suppress growth and induce 
apoptosis [44,45]. The clinical characteristics of colon cancer among statin users differ from 
non-users. The former have a lower tumor state, have a lower frequency of metastases, more 
frequently have a right-sited location of the tumor and have a significantly improved five-year 
survival rate (37% versus 33%, P-value < 0.01) [46].
The anticancer effects of statins have been studied in phases I, II, and III clinical trials in 
various malignancies (Table 3), with statin doses from 20 mg/day up to 45 mg/kg/day. Results 
vary, showing no (additional) effect of statins in multiple myeloma [47–49] and promising results 
in hepatocellular carcinoma [50]. Graf et al. [50] studied the addition of statins to transcatheter 
arterial chemoembolization (TACE) in hepatocellular carcinoma and found a significant gain 
in overall survival compared to TACE alone (median overall survival 20.9 months versus 12.0 
months, P = 0.003).
Lee et al. [51] recently reported results of a trial adding simvastatin to irinotecan, leucovorin 
and 5-FU (FOLFIRI) as first-line therapy in CRC patients. They based the hypothesis on a 
synergistic effect of these therapies in preclinical research. Response rates and overall survival 
were similar to historical results of FOLFIRI alone, but time to progression was prolonged (9.9 
months versus 6.7–8.5 months), and there was no additional toxicity.
These trials show promising activity of statins in solid tumors, yet further studies on statins 
in cancer therapy are needed.
Farnesyltransferase inhibitors
Prenylation is a necessary post-translational step for functional KRAS; for that reason, farne-
syltransferase inhibitors (FTIs) and geranylgeranyltranferase inhibitors (GGTIs) have been 
developed as anticancer therapy. Besides KRAS, other GTPases that promote tumor progression 
are prenylated. FTase can recognize and prenylate tetrapeptides with a CAAX sequence. FTIs 
act through two mechanisms. FPP analogs selectively compete with FPP for binding to FTase 
and the CAAX sequence of KRAS. The peptidemimetics competes with RAS-CAAX for FTase; 
some FTIs compete via both mechanisms. By these mechanisms, FTIs inhibit farnesylation of 
not only ras proteins but also various other polypeptides, such as nuclear lamins A and B, skeletal 
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Table 3: Phase I, II, and III trials evaluating statins in cancer treatment
Study Refs Study 
design
Tumor type Agent Additional 
agent
n Main results
Lee [51] Phase II CRC Simvastatin FOLFIRI 49 TTP 
possibly 
prolonged; 
no effect on 
RR or OS









Sondergaard [47] Phase II Multiple myeloma Simvastatin None 6 RR 0%
van der Speck [48] Phase II Multiple myeloma Simvastatin VAD 12 RR 8%
Schidmaier [49] Phase II Multiple myeloma Simvastatin Bortezomib or 
bendamustine
6 RR 0%
Knox [95] Phase I SCCHN/cervical 
carcinoma
Lovastatin None 26 RR 0%; CBR 
23%
Lersch [96] HCC Pravastatin versus octreotide 
versus gemcitabine




Kim [97] Phase II Gastric 
adenocarcinoma
Lovastatin None 16 RR 0%
Kawata [98] Phase III HCC Pravastatin TAE + oral 
5FU








Lovastatin ±Radiation 18 RR 11%; 
CBR 17%





Abbreviations: (m)OS, (median) overall survival; CBR, clinical benefit rate (i.e. complete and partial 
remission and stable disease); CRC, colorectal carcinoma; FOLFIRI, irinotecan, leucovorin and 5-FU; 
GBM, glioblastoma multiforme; HCC, hepatocellular carcinoma; RR, response rate (i.e. complete and 
partial remission); SCCHN, squamous cell carcinoma of head and neck; TA(C)E, transcatheter arterial 
(chemo)embolization; TTP, time to progression; VAD, vincristine, adriamycin, dexamethasone.
 
Four FTIs were tested in clinical trials worldwide: lonafarnib and tipifarnib (both oral 
compounds) have been tested in phase II and phase III studies (listed in Table 4), and BMS-
214662 and L-778,123, administered intravenously, were tested in phase I studies. Some of the 
trials listed in Table 4 tested tipifarnib and lonafarnib in solid tumors, such as breast, pancreatic, 
colorectal, urothelial and brain tumors, but the results of these trials were disappointing. 
Sparano et al. recently published the results of a phase II trial testing the addition of tipifarnib 
to neo-adjuvant doxorubicin–cyclophosphamide in patients with clinical stage IIB–IIIC breast 
cancer. The trial included 44 patients, and a pathological complete remission was seen in 25%, 
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compared to 10–15% for chemotherapy alone according to historical results. Still, the role of 
tipifarnib in the treatment of solid tumors remains unclear and further study is needed. In 
hematologic malignancies, however, tipifarnib did show some single-agent activity, especially 
in elderly patients with poor risk and previously untreated acute myeloid leukemia. Lancet et 
al. [54] tested tipifarnib monotherapy in this population and observed a response rate of 23%. 
Tipifarnib was submitted to the FDA for the treatment of acute myeloid leukemia in elderly 
patients not applicable for standard chemotherapy in January 2005. In June 2005, however, the 
FDA filed a Not Approvable Letter, awaiting the results of subsequent phase III trials of tipifarnib 
for this indication [55–57]. Recently, the results of a phase III trial comparing tipifarnib with 
best supportive care in newly diagnosed acute myeloid leukemia in patients of 70 years or older 
were published. The results showed no effect of tipifarnib on survival (median survival, 107 days 
versus 109 days; P-value, 0.843) [58].
Activation of KRAS by mutation is associated with radiotherapy resistance. Preclinical 
studies in vitro and in vivo with FTIs showed that the radiosensitivity of cells might be improved. 
The potential synergistic effect for radiosensitization might be the inhibition of activated KRAS 
by the FTIs [59–61].
A phase I trial of L-778,123 (an FTI and GGTI) and radiotherapy in 12 patients with pancreatic 
cancer showed acceptable toxicity. In a patient-derived pancreatic cell line, radiosensitization was 
observed. In total, eight patients completed treatment, one patient showed partial response for six 
months, five patients showed stable disease (>2 months) and two patients were progressive [62].
Another phase I trial with L-788,123 with radiotherapy in nine patients with locally advanced 
head and neck or lung cancer showed a complete response in one patient and five patients with 
a partial response [63].
Table 4: Phase II and III trials evaluating FTIs in cancer treatment
Author Refs Study 
design
Tumor Agent Additional agent n Endpoints 
and results
Harrousseau [58] Phase III AML Tipifarnib None 457 No effect on 
survival
Sparano [53] Phase II Breast cancer Tipifarnib Doxorubicin and 
cyclophosphamide
44 RR 77%




Lustig [102] Phase II GBM Tipifarnib Radiotherapy 28 RR 0%; CBR 
29%





Gemcitabine 244 No effect of 
the addition of 
tipifarnib on 
survival
Ravoet [104] Phase II MDS/AML Lonafarnib None 16 RR 6%
Feldman [105] Phase II MDS/CML Lonafarnib None 67 RR 4%; HI 
19%
Karp [106] Phase II AML Tipifarnib None 
(maintenance)
48 mDFS 13.5 
months
Fouladi [107] Phase II Glioma Tipifarnib None 97 RR 2%
Johnston [108] Phase II Breast cancer Tipifarnib None 120 RR 12%
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Author Refs Study 
design
Tumor Agent Additional agent n Endpoints 
and results
Harousseau [109] Phase II AML Tipifarnib None 252 RR 4%
Lancet [54] Phase II AML Tipifarnib None 158 RR 23%
Cloughesy [110] Phase II Glioma Tipifarnib None 
versus + EIAEDs




Whitehead [111] Phase II CRC Tipifarnib None 55 RR 7%
Borthakur [112] Phase II CML Lonafarnib None 13 RR 18%
Macdonald [113] Phase II Pancreatic 
cancer
Tipifarnib None 53 mOS 2.6 
months
Kim [114] Phase II NSCLC Lonafarnib Paclitaxel 33 RR 10%; CBR 
48%
Theodore [115] Phase II Urothelial 
cancer
Lonafarnib Gemcitabine 31 RR 32%
Winquist [116] Phase II Urothelial 
cancer
Lonafarnib None 19 RR 0%
Rosenberg [117] Phase II Urothelial 
cancer
Tipifarnib None 34 RR 6%; CBR 
44%
Rao [118] Phase III CRC Tipifarnib 
versus 
placebo
None 268 CBR 24% 
versus 13%; 
no effects on 
PFS and OS
Heymach [119] Phase II SCLC Tipifarnib None 22 RR 0%; mPFS 
1.4 months





Gemcitabine 688 mOS 193 days 
versus 182 
days
Kurzrock [121] Phase II MDS Tipifarnib None 28 RR 11%; 
severe toxicity
Alsina [122] Phase II Multiple 
myeloma
Tipifarnib None 43 RR 0%; CBR 
64%
Johnston [108] Phase II Breast cancer Tipifarnib None 76 RR up to 14%
Adjei [123] Phase II NSCLC Tipifarnib None 44 RR 0%; CBR 
16%
Cohen [124] Phase II Pancreatic 
cancer
Tipifarnib None 20 RR 0%; mOS 
19.7 weeks
Cortes [125] Phase II Multiple 
myeloma/
CML
Tipifarnib None 40 RR 18%
Sharma [126] Phase II CRC Lonafarnib None 21 RR 0%; CBR 
14%
Abbreviations: (m)DFS, (median) disease-free survival; (m)OS, (median) overall survival; (m)PFS, 
(median) progression-free survival; (N)SCLC, (non) small cell lung carcinoma; AML, acute myeloid 
leukemia; CBR, clinical beneficial rate (i.e. complete remission, partial remission and stable disease); CML, 
chronic myeloid leukemia; CRC, colorectal cancer; EIAEDs, enzyme-inducing antiepileptic drugs; GBM, 
glioblastoma multiforme; MDS, myelodysplastic syndrome; HI, hematologic improvement; RR, response 




Only inhibition of the farnesylation of KRAS by FTIs does not considerably affect its function, 
because KRAS can be geranylgeranylated as well. GGTase I geranylgeranylates KRAS when 
FTases are inhibited by FTIs. This fact triggered the development of GGTIs. GGPP analogs and 
CAAL peptidomimetics both act as GGTIs. Inhibition of KRAS prenylation might require co-
treatment of FTIs with GGTIs and might explain the limited efficacy of the FTIs as single drug 
[56]. Moreover, in contrast to FTIs, GGTIs are able to block phosphorylation of both PDGF- 
and EGF-dependent tyrosine kinase receptors. GGTase inhibitors have been tested in preclinical 
studies and showed decreased tumor growth (cell-cycle arrest in G1 and apoptosis) in vivo and 
in vitro [65–67]. Possibly because of the preclinical toxicity of GGTase I inhibitors, up till now 
they have not proceeded to clinical stages.
Bisphosphonates
Bisphosphonates (BPs) inhibit isopentenyl diphosphatase isomerase and FPP synthase 
and probably also GGPP synthase, two metabolites in the mevalonate pathway. The newer 
nitrogen- containing BPs (e.g. pamidronate and zoledronic acid), inhibited farnesylation 
and geranylgeranylation of KRAS, resulting in a decrease of downstream signaling, inducing 
apoptosis [5,64]. Other observed effects of BPs on tumor cells are inhibition of migration 
through and adhesion and invasion to the extracellular matrix, so-called ‘MMP activity’. At low 
concentrations, BPs inhibit the mevalonate pathway, whereas at higher concentrations, MMP 
activity is inhibited [68]. Furthermore, BPs reduce complications such as osteoporosis and 
skeletal morbidity caused by metastatic bone disease in metastatic and non-metastatic disease. 
In non-metastatic disease, BPs might prevent bone metastasis [69]; in metastatic disease, BPs 
might delay or prevent the complications caused by bone metastasis [70,71]. Clinical studies on 
BPs in cancer treatment have been performed, mainly focusing on endpoints regarding skeletal-
related events such as fractures and bone pain. Some of these trials also focus on response-related 
endpoints, to investigate the role of BPs in survival in cancer.
Table 5 shows the phase II/III clinical trials on BPs in cancer treatment, not (only) focusing 
on skeletal-related events. The largest and most recent trial was published by Gnant et al. [72], 
who tested the effects of the addition of zoledronic acid to either goserelin and tamoxifen or 
goserelin and anastrozole in pre-menopausal women with endocrine-responsive early breast 
cancer. After a median follow-up of 47.8 months, a disease-free survival rate of 94.0% was seen 
in the group receiving endocrine therapy with zoledronic acid, compared to 90.8% in the group 
receiving only endocrine therapy (P = 0.01) [72]. 
Nowadays, BPs are known to reduce bone loss owing to hormone therapy (such as for breast 
and prostate cancer) and prevent skeletal-related events [70]. Despite the results published by 
Gnant et al. [72], however, there is no consensus about the effect of BPs on survival.
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Table 5: Phase II and III clinical trials evaluating the effect of bisphosphonates on response 
related endpoints in malignancies.
Author Refs Study 
design
Tumor Agent Additional 
agent
n Endpoints and 
results






1803 Significantly longer 
disease-free survival 
with zoledronic acid




± docetaxel / 
±celecobrix
Ongoing trial
Diel [128] Phase III Breast Clodronate Adjuvant 
therapy
290 At 55 months follow 
up significantly 
improved PFS and 
OS with clodronate




953 No effect on 
occurrence of bone 
metastases




27 PSA response in 52%
RR 21%
Mason [131] Phase III Prostate Clodronate 
versus 
placebo
None 508 No effects on OS and 
bone metastases-free 
survival
Pavlu [132] Phase I/II CML Zoledronic 
acid
Imatinib 10 RR 0%
Di 
Lorenzo












22 PSA response in 23% 
RR in 14%






38 RR 0% versus 
65%. PFS and 
OS significantly 
improved
Lewis [136] Phase II Melanoma Apomine None 42 RR 0%, mPFS 6.1 
months
Bertelli [137] Phase II Prostate Zoledronic 
acid
Docetaxel 25 PSA response in 
48%, mild toxicity
Figg [138] Phase II Prostate Alendronate Ketoconazole 
and 
hydrocortisone
72 No significant 
differences in PFS, 
OS and RR
Tiffany [139] Phase II Prostate Zoledronic 
acid
Imatinib 15 No effects on pain 
and PSA
Dearnaley [140] Phase III Prostate Clodronate None 311 Non-significant 
better BPFS and OS





73 Time to development 
of (bone) metastases 
13 months versus 28 
months
Abbreviations: (m)PFS, (median) progression-free survival; BPFS, bone progression-free survival; CML, 
chronic myeloid leukemia; OS, overall survival; PSA, prostate-specific antigen; PSA response, >50% PSA 




After prenylation, KRAS undergoes endoproteolytic processing by the RCE1 protease and carboxyl 
methylation by ICMT. These enzymes, which act on both farnesylated and geranylgeranylated 
enzymes, could be targets for anticancer therapy.
Few small-molecule inhibitors of RCE1 and ICMT have been described so far. RPI, a prenylated 
CAAX peptide, competitively inhibits RCE1 as substrate analogs. Two types of ICMT inhibitors 
have been developed; both types act as mimics of substrates. The S-adenosylhomocysteines bind 
to methyltransferases and competitively inhibit the enzyme. In preclinical studies with cell lines, 
a partial block of proliferation was shown. Membrane-associated KRAS was reduced by 66% in 
one study, resulting in a decrease of downstream MEK/ERK signaling [73,74]. The second group 
of ICMT inhibitors contains derivatives of prenylcysteine: for example, N-acetyl-S-farnesyl-L-
cysteine and N-acetyl-S-geranylgeranyl- L-cysteine. These substrates act also as substrates for 
ICMT; however, they target other processes in the cell as well [75].
EGFR antibodies and KRAS
The EGFR is a target for anticancer therapy. EGFR is expressed in normal tissues and different 
tumors. The EGFR is a 170-kDa transmembrane receptor with an extracellular ligand binding 
domain, a transmembrane domain and an intracellular tyrosine kinase membrane. There are 
four EGFR-related receptors; EGFR (HER1), HER2, HER3 and HER4. The binding of the ligand 
to the ligand-binding domain results in a conformational change, enabling the receptor to form 
an EGFR–EGFR homodimer or an EGFR–HER2, EGFR–HER3 or EGFR–HER4 heterodimer 
(figure 5). The active dimer cause ATP-dependent phosphorylation of EGFR through tyrosine 
kinases, which cause proliferation, inhibition of apoptosis, invasion and metastasis [76].
Figure 5: Dimerization of the EGFR. The binding of a specific ligand (e.g. EGF) causes a conformational 
change and results in homodimer or heterodimer formation. Abbreviations: EGF, epidermal growth factor; 
EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor.
Monoclonal EGFR antibodies bind the extracellular domain of EGFR, thereby blocking the 
ligand-binding region, and as a result, the EGFR tyrosine kinase activation is halted and ras 
signaling is inhibited [76,77]. Cetuximab can induce antibody-dependent cell-mediated 
cytotoxicity (ADCC) and downregulation and degradation of EGFR and in this way exerts its 
anti-tumor activity. For panitumumab, no ADCC has been described [78].
Two EGFR antibodies, cetuximab and panitumumab, have been registered. Cetuximab is 
registered for the treatment of metastasized colorectal carcinoma with EGFR overexpression in 
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KRAS wild type patients (monotherapy or in combination with chemotherapy), head and neck 
squamous cell carcinomas in combination with radiotherapy, and metastasized head and neck 
squamous cell carcinomas in combination with cisplatin-based chemotherapy. Panitumumab 
is registered for colorectal carcinoma with EGFR overexpression in KRAS wild type patients. 
Retrospective analysis of clinical trials showed a lack of clinical activity of cetuximab and 
panitumumab in patients with mutant KRAS because mutant KRAS operates independently of 
activation of the EGFR [24,33,34,79–88]. Table 6 represents clinical studies on the efficacy of 
cetuximab or panitumumab in patients with CRC with either mutant or wild type KRAS tumors. 
These results indicate that the efficacy of panitumumab and cetuximab (mono-) therapy is 
limited to patients with wild type KRAS tumors [33,34,89,90].
Table 6: Studies investigating KRAS and cetuximab and panitumumab and KRAS status in 
colorectal carcinoma.





Douillard [91] FOLFOX4 ± panitumumab KRAS 
mutant
N/A 7.3 months N/A
KRAS 
wild type
-55 9.6 months N/A





-35 5.9 months 14.5 months
Van Cutsem 143 and 
144




7.6 months 17.5 months
KRAS 
wild type
38 (36.2) 9.9 months 24.9 months
Bokemeyer [81] FOLFOX-4 ± cetuximab KRAS 
mutant
17 (33) 5.5 months N/A
KRAS 
wild type
37 (60) 7.7 months N/A




(45.9) 8.1 months 17.2 months
KRAS 
wild type
(61.4) 10.5 months 21.8 months
Amado [33] Panitumumab versus BSC KRAS 
mutant
0 (0) 7.4 months 4.5 months
KRAS 
wild type
21 (17) 12.3 weeks 6.8 months
Karapetis [34] Cetuximab versus BSC KRAS 
mutant
(1.2) 1.9 months 4.8 months
KRAS 
wild type
(1.28) 3.7 months 9.5 months
Lievre 2008 Cetuximab ± chemotherapy KRAS 
mutant
0 (0) 9 weeks 10.1 months
KRAS 
wild type
34 (43.6) 31.4 weeks 14.3 months
Lievre 2006 [85] Cetuximab ± chemotherapy KRAS 
mutant
0 N/E 6.9 months
KRAS 
wild type
-65 N/E 16.3 months
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De Roock [82] Cetuximab ± irinotecan KRAS 
mutant
0 (0) 12 weeks 27.3 weeks
KRAS 
wild type
27 (21) 24 weeks 43 weeks
Khambata-
Ford
[24] Cetuximab KRAS 
mutant
3 (10) 59 days N/E
KRAS 
wild type
24 (48) 61 days N/E




0 (0) 3 months N/E
KRAS 
wild type
12 (27.9) 5.5 months N/E
Benvenuti [79] Cetuximab/panitumumab KRAS 
mutant
1 (6.2) N/A N/E
KRAS 
wild type
10 (31.2) N/A N/E
Frattini [146] Cetuximab KRAS 
mutant
1 (10) N/A N/E
KRAS 
wild type
9 (53) N/A N/E





30 8.3 months 17.8 months
KRAS 
wild type






47 10.4 months 19.3 months
KRAS 
wild type
50 9.8 months 20.7 months
Garm 
Spindler
[84] Irinotecan + cetuximab KRAS 
mutant
0 (0) 2.3 months 8.7 months
KRAS 
wild type
-40 8.0 months 11.1 months
Bibeau [80] Panitumumab versus BSC KRAS 
mutant
1 (4) 3.0 months 8.7 months
KRAS 
wild type
10 (27) 5.5 months 10.8 months
Prenen [87] Irinotecan ± cetuximab KRAS 
mutant
1 (1.3) 12 weeks 26 weeks
KRAS 
wild type
37 (30.3) 24 weeks 45 weeks




0 (0) 8.6 weeks
KRAS 
wild type





2 (20) N/E N/E
KRAS 
wild type
8 (38) N/E N/E
Loupakis [150] Irinotecan + cetuximab KRAS 
mutant
N/A 3.1 months 6.1 months
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N/A 4.2 months 13.5 months
Cappuzzo [151] Chemotherapy ± cetuximab KRAS 
mutant
4 (9.5) 4.4 months 9.5 months
KRAS 
wild type
10 (26.3) 5.4 months 10.8 months
Finocchiaro [152] Cetuximab KRAS 
mutant
(6.3) 3.7 months 8.3 months
KRAS 
wild type
(26.5) 6.3 months 10.8 months
Freeman [153] Panitumumab KRAS 
mutant










2 (6) N/A N/A
KRAS 
wild type
22 (28) N/A N/A












Abbreviations: BSC, best supportive care; N/A, not available (yet); N/E, not evaluated; OS, overall survival; 
PFS, progression-free survival; RR, response rate. The values in parentheses are the percentages of patients 
with RR.
Alternative strategies
An alternative strategy to attack KRAS mutated cells would be to inhibit targets downstream 
of ras, such as mTOR (using RAD001), PI3 kinase (using BEZ235) or raf (using BAY 43-9006). 
One could consider combining inhibitors of targets within the RAS-RAF-MAPK and PI3 kinase 
pathway, thereby possibly creating inhibition comparable to targeting of the EGFR. Inhibitors of 
various targets within these pathways have been tested in vivo and are currently being studied 
in phase I/II clinical trials (http:// www.clinicaltrials.gov). Because the efficacy of these agents 
has not been proved yet, however, none of them are standard in cancer therapy. Such alternative 
strategies might be relevant in the future in the treatment of patients harboring KRAS mutations.
Future perspectives
KRAS mutation status has an impact on the therapeutic opportunities for patients with colorectal 
carcinoma. Both cetuximab and panitumumab are effective only in KRAS wild type patients, 
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and in KRAS mutant patients, a worse response has been reported [81,91]. Modulation of 
KRAS prenylation in KRAS mutant tumors might potentiate EGFR therapy [92] because the 
metabolites formed during the mevalonate pathway have a key role in prenylation and thereby 
post-translational activation of KRAS. Indeed, inhibition of the mevalonate pathway could 
influence the potential of KRAS to translocate from the cytosol toward the membrane and, thus, 
alter the KRAS phenotype toward the wild type. Combinations of EGFR antibodies to target the 
EGFR with KRAS modulators such as statins, BPs, FTIs or GGTIs inhibitors targeting RAS-RAF-
MAPK signaling might augment the effect in patients with KRAS mutations. In (pre)clinical 
studies, further investigation should be done to elucidate the role of statins, FTIs, GGTIs, BPs, 
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Simvastatin in G13D KRAS mutated 
colorectal cancer cells render cells 





Statins are commonly used to reduce cholesterol levels and lower the cardiovascular 
risk. Beside cholesterol, also the formation of farnesylpyrophophate (a C15-group) and 
geranylgeranylpyrophosphate (a C17-group) are inhibited. These groups are used to activate 
the KRAS protein by prenylation (addition of a C15 or C17 group).   After prenylation, KRAS 
becomes more lipophilic and translocates from the cytosol to the membrane. In this study, we 
hypothesized that the cetuximab resistant phenotype of KRAS mutant cancer cells could be 
converted to a more KRAS wild type phenotype rendering the cells susceptible for cetuximab, by 
co-incubating cells with simvastatin. 
Method
Survival assays to measure proliferation were performed to study the effect of simvastatin, 
cetuximab and combination in the KRAS wild type A431 and KRAS mutant LoVo, HCT116 and 
SW480 cell lines. Furthermore KRAS localization assays as well as kinase activity assays were 
performed for all cell lines, to further explore the potential mechanisms.
Results
Simvastatin combined with cetuximab resulted in decreased proliferation in KRAS codon 
13 mutated cell lines. Especially in the KRAS G13D mutant LoVo cells a synergistic effect on 
inhibition of proliferation by the combination treatment was observed.  After incubation with 
simvastatin more KRAS protein was situated in the cytoplasm in KRAS mutant cells compared to 
control cells. The EGFR target pathway is controlled by tyrosine kinase activities, which showed 
synergistic inhibition in LoVo cells. Simvastatin elevated Serine/Threonine kinase activities, 
including AKT and NOS phosphosites, which is in accordance to previous reports. 
Conclusion
In summary, we observed a synergistic effect of adding simvastatin to cetuximab treatment in 
inhibition of KRAS codon 13 mutated CRC cell proliferation. The mechanism of action appears to 
involve aberrant translocation of KRAS likely due to lack of prenylation and enhanced inhibition 
of tyrosine kinase signaling.
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Introduction
Epidermal growth factor receptor (EGFR) signaling plays an important role in proliferation of 
cells, and therefore blocking this pathway has emerged as an effective drug target in oncology. 
Cetuximab and panitumumab are two registered EGFR antibodies. Patients with advanced or 
metastasized colorectal carcinoma (CRC) failing fluorouracil (or alternatives such as capecitabine 
or uracil and tegafur, oxaliplatin and irinotecan) can be treated with chemotherapy combined 
with one of these anti-EGFR monoclonal antibodies. However, cetuximab and panitumumab 
have both been registered for the use in patients with KRAS wild type tumors only, since 
retrospective analyses of clinical trials showed a lack of efficacy in KRAS mutated colorectal 
tumors. Unfortunately, approximately 40% of patients with colorectal cancer have a somatic 
KRAS mutation, which leads to a constant expression of KRAS protein, operating independently 
of EGFR and thus EGFR antibody resistance. As a result, a considerable group of CRC patients 
is excluded from therapy with cetuximab or panitumumab and does not benefit from EGFR 
antibody treatment [1]. 
KRAS can be mutated at several positions, 90 % of the activating KRAS mutations occur at 
codon 12 and 13[2]. Membrane association of the KRAS protein is crucial for its function as a 
switch in the signal transduction pathway between EGFR and the nucleus. To achieve this, the 
hydrophilic KRAS protein is farnesylated (addition of farnesylpyrophosphate, a farnesylgroup), 
or geranylgeranylated (addition of a geranylgeranylpyrophosphate, a geranylgeranylgroup). As a 
result, KRAS becomes more lipophilic and translocates from the cytosol to associate with the cell 
membrane. This so-called prenylated active KRAS exerts its function in the cellular membrane 
[3,4]. Statins are known to inhibit the conversion of 3-hydroxy-3-methyl-glutaryl Co-enzyme A 
(HMG-CoA) to mevalonate, a precursor for cholesterol synthesis; this reduces the cholesterol 
synthesis and thus the formation of low-density lipoprotein. Beyond their lipid lowering effects, 
statins are extensively studied for their effects on cellular proliferation in cancer. As shown 
in in vitro studies, simvastatin affects angiogenesis, apoptosis as well as the inflammation 
processes. [5-8] Another important effect of statins, although less studied, is the interference 
with the formation of farnesyl- and geranylgeranylgroups. These groups are formed as part of 
the mevalonate cascade and are crucial for the prenylation of proteins, such as KRAS. Since 
farnesyl- and geranylgeranyl moieties are essential for post-translational prenylation, and thus 
for activation of KRAS. Statins may have the potential to phenoconvert KRAS mutated tumors 
into a more KRAS wild type and thus EGFR inhibitor sensitive phenotype [9,10]. 
In this proof of concept study we hypothesized that phenoconversion of KRAS mutant 
colorectal cancer cells could be achieved by simvastatin, rendering colorectal cancer cells sensitive 
for cetuximab. In this study, cell growth survival assays were used to investigate a possible 
synergistic effect of simvastatin on cetuximab sensitivity in several KRAS mutant colorectal 
cancer cell lines and in wild type EGFR overexpressing cell line. The effect of simvastatin on 






The human colorectal cancer cell lines LoVo (KRAS mutation G13D), HCT116 (KRAS mutation 
G13D), SW480 (KRAS mutation G12V), and the human epidermoid carcinoma cell line A431 
(wild type for KRAS and over-expressing EGFR) were obtained from American Type Culture 
Collection-ATCC (Manassas VA, USA). These cell lines were selected using the information 
about KRAS mutations in the Cancer Genome Project (http://www.sanger.ac.uk/genetics/CGP/
CellLines/). Cell lines harbouring a KRAS mutation in codon 12 or 13 were selected because 
these mutations are most common in colorectal cancer. Cells were grown in RPMI 1640 medium 
(Invitrogen, Breda, The Netherlands) supplemented with 10 % fetal bovine serum (Greiner Bio-
One GmbH, Frickenhausen, Germany) and 1% penicillin/streptomycin (Invitrogen, Breda, The 
Netherlands) in a 5% CO2 atmosphere at 37 °C. When applicable, cells were detached from flasks 
with Trypsin-EDTA solution (Invitrogen, Breda, the Netherlands). Cells were cultured for a 
maximum of 20 passages. Cetuximab was kindly provided by Merck (Darmstadt, Germany). 
Simvastatin was obtained from Fagron (Nieuwerkerk a/d IJssel, The Netherlands) and was 
chemically activated by alkaline hydrolysis prior to use as described before [11]. Simvastatin was 
selected because this statin is most commonly prescribed in Europe.
Cell survival
The effects of simvastatin and cetuximab as single agents or in combination on survival of the 
cells, were evaluated using the sulphorhodamine binding (SRB) colorimetric assay as described 
by Skehan et al. [12] with minor modifications. Cells were harvested by trypsinization, counted 
and plated in 96-well plates at a density of 5 x 103 cells per well (100 µL/well). Following overnight 
incubation, cells were pre-treated with simvastatin (2 μM). After 24 hours of incubation, cells 
were co-treated with cetuximab (500 µg/ml) and incubated for another 48 hours. At the end of 
the incubation, the SRB assay was performed as described below. Cells were fixed by addition of 
25 µl ice-cold 50% trichloroacetic acid (TCA) to the growth medium. The plate was incubated 
at 4°C for 1 hour and then the cells were gently washed three times with milli-Q water. After 
drying at room temperature, cells were stained with 50 µl of 4% sulphorhodamine (w:v dissolved 
in 1% acetic acid) for 30 min. At the end of the staining period, unbound sulphorhodamine was 
removed by washing three times with 1% acetic acid. The plates were air dried and bound SRB 
was dissolved in 200 µl of 10 mM Tris-base (pH 10.5). Next, the plate was shaken followed by 
reading the optical density (OD) at 550 nm in a microplate spectrophotometer (Spectramax 
190, Molecular Devices, Sunnyvale, USA). Results are expressed as the relative percentages of 
absorbance compared to controls, which were not exposed to drugs. Results of OD measurements 
are expressed as a percentage of cell proliferation of the controls. Results are expressed as means 
with corresponding standard deviations of three independent experiments in at least fourfold. 
Statistical analysis was performed using SPSS, a two-sided t-test were performed and p-values 
<0.05 were considered significant.
Membrane association of KRAS
Cell were seeded in a 6 wells plate at a density of 5 x 105cells per well. After overnight incubation, 
cells were incubated for 24 hours according to the following conditions: vehicle as negative 
control, 2 µM simvastatin or with 2 µM of the geranylgeranyltransferase inhibitor GGTI-298 
(Merck, Darmastadt, Germany). GGTI-298 is known to inhibit prenylation and therefore taken 
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as positive control. Next, cells were trypsinized and membrane and cytoplasm fractions were 
separated using Subcellular Protein Fractionation Kit for Cultured Cells (Thermo Scientific, 
Breda, The Netherlands). Protein concentration was determined using BCA protein assay kit 
(Thermo Scientific, Breda, The Netherlands). Presence of KRAS protein in membrane and 
cytoplasm fractions was analysed by western blotting. Equal amounts of cell lysates were loaded 
on 11% SDS-PAGE gels. After blotting on nitrocellulose membrane, the blot was cut in two to 
detect KRAS and Actin (as internal control) in the same lane. Primary antibodies against KRAS 
(RAS (D2C1), Cell Signaling Technology, Leiden, The Netherlands) and Actin (actin (13E5), 
Cell Signaling Technology, Leiden, The Netherlands)) were used in this study. Anti-rabbit IgG, 
HRP-linked antibody and LumiGlo (Cell Signaling Technology, Leiden, The Netherlands) was 
used to visualize the proteins bands on Chemidoc from Biorad (Veenendaal, the Netherlands).
Kinase activity profiling
Cells, counted and plated in 6-wells plates at a density of 1 x 106 cells per well (2 mL/well) were 
harvested by trypsinization. Following overnight incubation, cells were pre-treated with 2.0 μM 
simvastatin or vihicle for 24 hours and another 24 hours with wicicle, simvastatin, cetucimab 
or combination. At the end of the incubation, cells were lysed using M-PER Lysis buffer 
(Fischer Thermo Scientific, Rockford, USA) supplemented with Protease inhibitor Cocktail 
and phosphatase Inhibitor cocktail (Fischer Thermo Scientific, Rockford, USA) (1 million cells 
per 100 µl). The protein content was determined with Pierce BCA Protein Assay Kit (Thermo 
Scientific, Breda, The Netherlands). Protein serine/threonine kinase activity and tyrosine kinase 
activity was determined in triplicate using Pamgene’s Serine/Threonine Kinase (STK) peptide or 
tyrosine kInase (PTK) microarrays (Pamgene, ‘s-Hertogenbosch, the Netherlands), according 
to the manufacturers’ instructions [13]. All microarray data processing and visualizations were 
performed using Bionavigator and Matlab software (R2010B, The Mathworks, Natick, MA) as 
described before[14]. For the serine/threonine kinase assay 109 peptides were included in the 
analysis, for the PTK assay, 89 peptides were included and analysed in the R-package ‘multcomp’ 
using Dunnett contrasts. For pathway analysis, substrate peptides that showed a significantly 
different (p<0.05) phosphorylation pattern between vehicle and simvastatin, cetuximab or 
combination were used as input to identify pathways with differential activity using GeneGo 
Metacore (Thomson Reuters). The peptides were linked to the UniProt ID’s of the proteins that 
they were derived from Uni-Prot database (www.expasy.org) and these were used for a pathway 
analysis.
Results
Effect of simvastatin and cetuximab on survival of KRAS mutant and wild type cell lines
The cytotoxicity of simvastatin was first tested in a concentration range from 0.1 to 2.0 µM (data 
not shown). A minimal cytotoxic effect was observed and therefore a concentration of 2.0 µM of 
simvastatin was used in the experiments to inhibit the mevalonate pathway and the formation 
of farnesyl- and geranylgeranylgroups. Incubation of the KRAS wild type A431 cell line with 
500 µg/ml cetuximab resulted in a decrease of survival to 66 ± 3.3 % compared to untreated 
cells (p=0.045) (figure 1). The combination of both simvastatin and cetuximab diminished cell 
growth further to 56 ± 4.1 %, but this was not significantly different from the growth inhibitory 
effect of cetuximab as single agent (p=0.228). Incubation of LoVo and HCT116 cells, both 
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harbouring a KRAS G13D mutation, with 500 µg/ml cetuximab resulted in a non-significant 
survival reduction of 84 ± 11.1 % and 99 ± 5.5 %, respectively compared to control. In these cell 
lines, compared to control, simvastatin monotherapy (2 μM) resulted in a survival of 76 ± 9.0 
% for LoVo and 84 ± 7.5 % for HCT116. Combined treatment with simvastatin and cetuximab 
reduced the proliferation in LoVo further to 47 ± 4.9 %, which is significantly different from the 
growth inhibitory effect of either cetuximab (p<0.001) or simvastatin (p<0.001) as single agents. 
In HCT116 the same synergistic effect was seen, combination therapy significantly reduced the 
survival to 68 ± 5.6 % compared to simvastatin alone (p<0.002) or cetuximab alone (p<0.001). 
No synergistic effect was observed in SW480 cells (KRAS G12V) when treated with simvastatin 
and cetuximab as well. Incubation with 500 µg/ml cetuximab did not result in a decrease of 
survival (102 ± 1.7 % p=1.00). Simvastatin (2 µM) as single agent resulted in survival of 79 ± 
7.5%. Compared to treatment with simvastatin alone, the combination with cetuximab, did not 

































































































































Figure 1: Cell proliferation assays (Sulforhodamine-B assays) of three KRAS mutant (LoVo, HCT 116 and 
SW480) and one KRAS wild type cell line treated with simvastatin, cetuximab or the combination for three 
days. The results of the measured optical density are expressed as a percentage of cell proliferation compared 
to the untreated controls. Results are means and the 95 % confidence intervals of three independent 
experiments in at least fourfold.
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KRAS translocation
To test whether the observed synergistic effect was the result of decreased KRAS activation, the 
effect of simvastatin on the prenylation of mutated KRAS was analysed in LoVo and HCT116 
cells. Membrane and cytoplasm fractions of cells incubated with simvastatin were tested for 
KRAS localization. In both cell lines, KRAS was mainly localized in membranes of the cell. 
Upon simvastatin treatment, an increase of KRAS concentrations in the cytoplasm of LoVo and 
HCT116 cells was observed (figure 2a and 2b). This was also seen in presence of the positive 
control GGTI-298 (Sigma-Aldrich, the Netherlands) an established prenylation inhibitor. 
Figure 2 a and b: Western blot ana-
lysis showing the amount of KRAS 
in the cytoplasm and membrane 
after treatment with the positive 
control GGTI-298 or simvastatin in 
KRAS mutant G13D HCT116 cells 




As described above, a clear synergistic effect of simvastatin on cetuximab treatment was observed 
in LoVo cells. Therefore, PTK and STK activity was explored for these cells at different treatment 
conditions. STK activity reflects downstream signaling of KRAS. In LoVo cells, treatment with 
cetuximab or simvastatin as single agents display a strong activated STK activity, nearly all 
peptides on the STK array became significantly phosphorylated. Because of this strong effect, no 
conclusion could be drawn. PTK activity reflects EGFR signaling, upstream of KRAS. Cetuximab 
and simvastatin as single agents showed only a slight effect on PTK activity, however, combination 
of both drugs show a clear synergistic effect displayed by decreased PTK activity (figure 3A and 
3B). In all other cell lines (A431, HCT116 and SW480), this synergy was not observed. 
Figure 3a: STK activity profiles. Significant (p < 0.05) log ratio of signal intensity versus the control sample 
for cell lines A431, HCT116 and LoVo, treated with simvastatin, cetuximab or combination. Each column 
represents a sample, each row a peptide. The relative signal with respect to control is indicated by the color 
intensity: red implies higher, blue lower than control. 
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Figure 3b: PTK activity profiles. Significant (p < 0.05) log ratio of signal intensity versus the control sample 
for cell lines A431, HCT116 and LoVo, treated with simvastatin, cetuximab or combination. Each column 
represents a sample, each row a peptide. The relative signal with respect to control is indicated by the color 
intensity: red implies higher, blue lower than control. 
Discussion
In this study we investigated if phenoconversion of KRAS mutant colorectal cancer cells by 
simvastatin could be achieved in order to restore sensitivity of KRAS mutant cells to anti-
EGFR treatment. We also explored overall kinase activity upon treatment. Our study shows that 
simvastatin affects KRAS localization and that simvastatin treatment of cells results in decreased 
membrane association of KRAS. Furthermore, KRAS codon 13 mutant cells become sensitive 
for cetuximab in presence of simvastatin. Exploring kinase activity revealed a decrease in PTK 
activity in LoVo cells upon treatment with simvastatin together with cetuximab, explaining the 
significant decrease in cell survival.
The proliferation of KRAS G13D mutated LoVo and HCT116 cell lines was significantly 
inhibited in presence of both drugs, whereas the individual drugs have no or only a minimal effect 
on cell proliferation. However, in the SW480 cell line, harbouring a KRAS codon 12 mutation 
the combined therapy of cetuximab and simvastatin did not significantly affect the proliferation. 
This indicates that not all KRAS mutations in colorectal cancer cells have a similar effect on anti-
EGFR sensitivity, although other mutations should also be taken into account. In a recent study 
computational analysis revealed that the codon 13 mutated KRAS protein has a similar structure 
compared to the wild type protein [15]. This similar structure of KRAS may contribute to difference 
in effect between KRAS 12 and 13 mutations observed in this study. Also retrospective analysis in 
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patients showed that patients with G13D mutant colorectal tumor might respond to cetuximab 
treatment[16,17]. Our findings are in agreement with the preclinical study of Lee et al. [18] 
who also showed that simvastatin might overcome cetuximab resistance in colorectal cancer by 
modulating BRAF activity, an important kinase in the RAS-RAF–MAPK signaling pathway[19]. 
Other studies showed that simvastatin also affects angiogenesis, apoptosis and the inflammation 
processes [5-8] but at higher concentrations (up to 50 μM). In our experiments a low simvastatin 
concentration of 2 μM was used, aiming at affecting only the prenylation of KRAS without a 
direct cytotoxic effect. Of note, KRAS mutant cells are more susceptible simvastatin than the wild 
type KRAS cell line. A possible explanation for this is a strong dependence (addiction) of the 
mutant cells on permanently activated KRAS and its corresponding pathways. A recent preclinical 
study [20] showed that simvastatin indeed inhibited the geranylgeranylation of the KRAS 
protein and this inhibition could be reversed with addition of geranylgeranylpyrophosphate. The 
geranylgeranyltransferase inhibitor GGTI-298 was used as a positive control in the Westernblot 
experiments. Incubation with this inhibitor indeed resulted in elevated levels of KRAS in the 
cytoplasm. Western blot analysis used here showed that membrane association of mutant KRAS is 
inhibited by simvastatin in the KRAS G13D cell lines LoVo and HCT116. This effect is most likely 
caused by a decrease in prenylation of the KRAS protein after simvastatin treatment. 
The phosphorylation pattern was clearly affected by simvastatin in the KRAS mutated cell 
lines. Whereas this effect was absent in the wild type cell line. The differences in kinome profiles 
after simvastatin treatment also supports the aforementioned dependence on KRAS signaling in 
KRAS mutant cell lines. The results from the kinome analysis showed that simvastatin altered the 
KRAS dependant signaling in the cancer cell lines, especially in KRAS codon 13 mutated cells. 
Pamchip STK data revealed, most clearly seen in LoVo cells, an abundant STK activity (of which 
PKB/AKT). These findings are in accordance with the findings of Kureishi et al.[21]. Skaletez-
Rorowski[22] showed that low doses of statins promote AKT activation while high doses result 
in toxicity and cell death[23]. Because of the tremendous STK activity detected in LoVo cells, 
more subtle effects downstream of KRAS could not be observed by the Pamchip array. However, 
the observed synergistic effect of simvastatin and cetuximab on KRAS codon 13 mutated cells, 
could well be explained by Pamchip PTK data. EGFR is a tyrosine kinase receptor of which 
signaling could be blocked by cetuximab. As expected, LoVo cells show a decreased PTK activity 
upon incubation with cetuximab. Hardly any effect was seen upon simvastatin treatment, also 
as expected since simvastatin was considered to affect only STKs. Interestingly, the synergistic 
effect of both drugs on cell survival was also seen on PTK activity. As mentioned before, conform 
the results of Lee et al [24] simvastatin and cetuximab synergise after BRAF (effector protein 
downstream of KRAS) modulation. A recent report by Prahallad et al. [25] showed that blocking 
mutated BRAF by vemurafenib resulted in feedback activation of EGFR. Indeed, these cells 
became sensitive for cetuximab. Taken together, their and our findings, interfering in the signaling 
pathway downstream of KRAS (by simvastatin or vemurafinib), results in feedback activation of 
EGFR. Consequently, PTK activity is diminished upon treatment by both drugs. 
In conclusion, the cetuximab resistant phenotype of KRAS codon 13 mutated cell lines, could 
be converted to a more KRAS wild type cell line (which is moderately sensitive to cetuximab) 
by co-treatment with simvastatin. The mechanism behind this phenoconversion is interfering 
in membrane association of KRAS most likely by inhibition of prenylation of KRAS. Interfering 
in the pathway downstream of KRAS results in a feedback mechanism of EGFR, resulting in a 
synergistic effect of simvastatin on cetuximab treatment. The latter conclusion is confirmed by 
the observed decreased PTK activity. 
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Statin use is not associated with 
improved progression free survival 
in cetuximab treated KRAS mutant 
metastatic colorectal cancer patients: 





Statins may inhibit the expression of the mutant KRAS phenotype by preventing the prenylation 
and thus the activation of the KRAS protein. This study was aimed at retrospectively evaluating 
the effect of statin use on outcome in KRAS mutant metastatic colorectal cancer patients (mCRC) 
treated with cetuximab. 
Method
Treatment data were obtained from patients who were treated with capecitabine, oxaliplatin 
bevacizumab ± cetuximab in the phase III CAIRO2 study. A total of 529 patients were included 
in this study, of whom 78 patients were on statin therapy. 
Results
In patients with a KRAS wild type tumor (n=321) the median PFS was 10.3 vs. 11.4 months for 
non-users compared to statin users and in patients with a KRAS mutant tumor (n=208) this 
was 7.6 vs. 6.2 months, respectively. The hazard ratio (HR) for PFS for statin users was 1.12 
(95% confidence interval 0.78 -1.61) and was not influenced by treatment arm, KRAS mutation 
status or the KRAS*statin interaction. Statin use adjusted for covariates was not associated with 
increased PFS (HR= 1.01, 95% confidence interval 0.71 – 1.54). In patients with a KRAS wild 
type tumor the median OS for non-users compared to statin users was 22.4 vs. 19.8 months and 
in the KRAS mutant tumor group the OS was 18.1 vs. 14.5 months. OS was significantly shorter 
in statin users versus non-users (HR =1.54; 95% confidence interval 1.06-2.22). However, statin 
use, adjusted for covariates was not associated with increased OS (HR= 1.41, 95% confidence 
interval 0.95 – 2.10). 
Conclusion
In conclusion, the use of statins at time of diagnosis was not associated with an improved PFS 
in KRAS mutant mCRC patients treated with chemotherapy and bevacizumab plus cetuximab.
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Introduction
Statins are widely prescribed to lower blood cholesterol concentration and have shown to reduce 
the risk of cardiovascular events and mortality [1]. In addition, the use of statins have been 
associated with a reduced risk of malignancies in a variety of organ sites, such as colon, rectum, 
lungs and liver[2]. Statins inhibit cholesterol synthesis via inhibition of the mevalonate pathway 
but also lower protein prenylation (figure 1). As a posttranscriptional process, protein prenylation 
is crucial for several cancer cell growth related proteins, such as KRAS. The KRAS protein is 
activated by post-translational prenylation by binding farnesyl (C15) and geranylgeranyl (C17) 
moieties, both products of the mevalonate pathway. After prenylation the KRAS protein becomes 
lipophilic and translocates to the cellular membrane to exerts its function[3].
Epidermal Growth Factor Receptor (EGFR) inhibitors, such as cetuximab and panitumumab, 
have shown survival benefit in combination with chemotherapy and as monotherapy in metastatic 
colorectal cancer (mCRC) patients [4]. Their benefit is restricted to patients with a KRAS exon 2 
wild type tumor[5], which recently was further narrowed to RAS wild type exon 2-4 tumors [6]. 
In patients with a KRAS mutated tumor, the RAS pathway is permanently activated, leading to 
constant cell signaling and proliferation independent of the EGFR.
Statins may inhibit the expression of the mutant KRAS phenotype by preventing the 
prenylation of the KRAS protein and normalize the phenotype into KRAS wild type and therefore 
render KRAS mutant colorectal cancers sensitive to EGFR antibodies[7]. We hypothesize that 
KRAS mutant cetuximab treated CRC patients with concurrent statin use have a favourable 
outcome from EGFR therapy compared to non-users. This study was aimed at retrospectively 
evaluating the effect of statin use in KRAS mutant mCRC patients treated with cetuximab.
Materials and methods
Patients
For this analysis prospectively collected data were obtained from mCRC patients participating in 
the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). Patients were randomised 
between capecitabine plus oxaliplatin (CAPOX) and bevacizumab, study arm A, and the same 
regimen plus cetuximab, study arm B (ClinicalTrials.gov NCT00208546 [8]). Cetuximab was 
administered at a dose of 400 mg/m2 on the first day followed by 250 mg/m2 weekly thereafter. 
Details of eligibility criteria and results have been reported elsewhere[8]. Patients with a tumor 
with an unknown KRAS mutation status were excluded from this analysis.
Drug exposure
Statin use was defined as the use of a statin at visit 0, the randomisation or at visit 1, 3 weeks after 
start of treatment. All statins (ATC-codes C10AAXX), commercially available in The Netherlands 
within the study period were included: simvastatin, pravastatin, atorvastatin, rosuvastatin and 
fluvastatin. 
Potential confounders
Use of drugs related to progression and development of colorectal carcinoma such as non-
steroidal anti-inflammatory drugs (NSAID’s), aspirin, fibrates and bisphosphonates at visit 0 or 
1 were considered as potential confounders. The use of these drugs was recorded. If the use of 
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these drugs in the study population was less then <1%, the drug was excluded from the further 
analysis. The use of fibrates was excluded, from the analysis because of the low prevalence (<1%).
Figure 1: Overview of the mevalonate pathway and the inhibition of HMG-CoA by statins
Mevalonate pathway causes prenylation of ras, N-glycosylation of EGFR and membrane and steroid-
synthesis. Statins inhibit HMG-CoA reductase and thus the prenylation of KRAS. Abbreviations: Acetyl-
CoA, Acetyl coenzyme A ; EGFR, epidermal growth factor receptor; FTase, farnesyltransferase; GTase, 
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Outcome measures
The primary outcome measure in this study was to assess the influence of statin use during 
chemotherapy with CAPOX-bevacizumab and cetuximab on progression free survival (PFS) in 
patients with KRAS mutant CRC. Furthermore, we examined the influence on overall survival (OS).
Statistical analysis
Baseline characteristics were compared between statin users and nonusers using a χ2 test for 
categorical comparisons and for continuous variables the Student’s t-test was used.
PFS was calculated as time from randomisation to the first documented progression, death 
or last follow up, whichever came first. OS was calculated as time from randomisation to death or 
last follow up. Kaplan-Meier survival estimates were calculated to determine the effect of statin 
use on PFS and OS in the cetuximab treated group by stratifying the study population into two 
groups according to KRAS status. For comparison between the statin users and non-users a log-
rank test was used. 
Cox proportional hazard models were used to determine whether the statin use in patients 
with KRAS mutant tumors treated with cetuximab was a significant predictor of PFS and 
OS. Instead of a subgroup analysis based on KRAS status and treatment arm, we used a Cox 
proportional hazard model, to study the effects of statins in cetuximab treated patients and 
compare it to non-cetuximab users to exclude a general statin effect. The following parameters 
were used in the model, statin use, KRAS mutation status, treatment arm, allowing for a different 
effect of statins between KRAS mutant and wild type tumors by means of an effect modifier in 
the model. In the multivariate analysis we included potential confounders with a p-value of <0.10 
from the baseline univariate analysis, between statin user and non-users. 
The deviating baseline characteristics between statin users and non-users with a p-value 
of <0.1 were also included in the multivariate analysis, e.g. prior adjuvant therapy, number of 
affected organs, and age. 
The data are expressed as hazard ratios (HR), 95% CI intervals and P values. All statistical 
tests were two sided and p values <0.05 were considered statistically significant unless stated 
otherwise. All statistical analyses were performed using SPSS version 20 (SPSS for Windows, 
SPSS Inc., Chicago, IL, USA).
Results
Baseline patient characteristics according to statin use
795 patients were enrolled in the CAIRO2 study. A total of 529 patients from the CAIRO2 study 
were included in this analysis, 266 patients were excluded based on unknown KRAS mutation 
status, due to retrospective genotyping of the KRAS mutation status of the tumor, because 
the CAIRO2 study was performed in the pre KRAS era. A total of 78 patients were on statin 
therapy, of whom 43 patients were classified in treatment group A CAPOX-B and 35 in group B, 
CAPOX-B with cetuximab. 451 patients did not use a statin, of whom 225 patients were in group 
A and 226 to group B. The study population is described in table 1. It is noteworthy that patients 
in the statin group were older (67.1 vs. 61.9 p<0.001), more likely to be an aspirin user (44.9% vs. 
6.4% p<0.001) and had a lower number of affected organs ( >1 organ: 48.7% vs. 60.3% p=0.049) 
compared to patients who were not on statins. These deviating baseline characteristics between 
statin users and non-users with a p-value of <0.1 were included in the multivariate analysis.
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NSAID user 6 (7.7) 45 (10.0) 0.528
Aspirin user 35 (44.9) 29 (6.4) <0.001
Bisphophonate user 2 (2.6) 5 (1.1) 0.299
Fibrate user 1 (1.3) 1 (0.2) -
Effect of statin use on progression free survival
Statin use alone did not have a statistically significant effect on PFS of cetuximab treated patients 
with a KRAS mutant tumor (figure 2). In patients with a KRAS wild type tumor, the median 
PFS was 10.3 vs. 11.4 months (p=0.882) for nonusers compared to statin users, and in the KRAS 
mutant group 7.6 vs. 6.2 months (p=0.291), respectively. The hazard ratio (HR) of PFS was 1.12 
(95% confidence interval 0.78 -1.61) and was not influenced by treatment arm, KRAS mutation 
status or the KRAS*statin interaction. 
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In the multivariate analysis, the covariate adjusted HR for PFS was 1.01 (95%CI 0.71-1.54) for 
statin users. 
Figure 2: Kaplan-Meier plots for progression free survival for patients with KRAS wild type (19 statin users 
and 145 nonusers) and KRAS mutant (16 statin users and 83 nonusers) tumors treated with capecitabine, 
oxaliplatin, bevacizumab and cetuximab. 
Figure 3: Kaplan-Meier plots for overall survival for patients with KRAS wild type (19 statin users and 145 
nonusers) and KRAS mutant tumors (16 statin users and 83 nonusers) treated with capecitabine, oxaliplatin, 
bevacizumab and cetuximab.
 
Effect of statin use on overall survival
Among patients with a KRAS wild type tumor, the median OS for non-users compared to statin 
users was 22.4 vs. 19.8 months (p=0.650), in patients with a KRAS mutant tumor the median OS 
was 18.1 vs. 14.5 months (p=0.125) (figure 3), respectively. The OS was different between statin 
users and non-users (HR =1.54 for statin users 95% confidence interval 1.06-2.22) in the crude 
analysis. However, the covariate adjusted hazard ratio for OS was not associated with increased 




The results of this cohort study of patients diagnosed with metastatic CRC show that the use of 
statins is not associated with an improved PFS in patients with KRAS mutant tumors treated with 
cetuximab. 
To the best of our knowledge, this is the first study investigating the effects of statin use on 
outcome in metastatic CRC patients in relation to KRAS mutation status and use of cetuximab. 
Preclinical studies have shown the antitumor effect of statins in CRC by a variety of mechanisms 
on cell proliferation. The leading hypothesized mechanism of statins is the inhibition of 
farnesylation of the KRAS protein[7,9]. We hypothesized that KRAS mutant CRC treated with 
cetuximab benefit from statin use, because statins may phenoconvert the overactive KRAS 
protein to a more wild type KRAS phenotype and thereby render these tumors sensitive to 
cetuximab treatment. Instead of stratifying for KRAS status and treatment arm and performing 
a subgroup analysis, a Cox proportional hazard model in the complete cohort of 529 patients 
was used, allowing for a different effect of statins between KRAS mutant and wild type tumors 
by means of an effect modifier. This study design allows to exclude a possible “generic” effect 
of statins on survival, because patients with a KRAS wild type tumor and patients in the arm 
without cetuximab were also included in the analysis. We did not observe an effect of statin 
use on the wild type KRAS tumors and thus no effect on cetuximab sensitivity. Moreover, we 
found no association between statin use and progression-free or overall survival in patients with 
a mutant KRAS tumor and therefore our study results do not support our hypothesis. 
A possible explanation for the lack of effect of statins is that the cohort existed of patients 
with CRC with metastatic disease and hence a relatively short progression-free survival to 
demonstrate a modulating effect of statins on the efficacy of cetuximab. Secondly, in preclinical 
studies high doses of statins are used to treat cancers, aiming at inducing a cytotoxic treatment 
effect. The high concentrations used in those in vitro cell cultures are most likely not reached if 
the registered dose of statin for cardiovascular prevention is prescribed[10]. On the other hand, 
the registered doses decrease cholesterol levels and subsequently, the formation of prenylgroups, 
is reduced and as a consequence the prenylation of KRAS is inhibited[11].
This retrospective cohort study has some limitations. The included patients used different 
doses and statin types. We did not analyse the type, duration or dose of statin given, so we were 
unable to access the individual effect of these characteristics on the endpoints of the study. 
The bioavailability, pharmacokinetics and pharmacodynamics could be significantly different, 
however, we expect that patients were adequately treated for hypercholesterolemia as it is common 
practice to titrate patients based upon monitoring of their cholesterol levels. The proposed effect 
of the statins in this study is inhibition of formation of farnesyl- and geranylgeranylgroups which 
are essential for KRAS activation and also closely related to the main statin effect namely HMG-
CoA reductase inhibition. Therefore, all statins could be combined in this study. Since patients 
included in this study were on stable statin dose, we assumed that target levels of cholesterol were 
reached. Consequently, this also implies that effective inhibition of formation of farnesyl- and 
geranylgeranylgroups was reached at the individualized statin dose. We thoroughly screened the 
patients’ co-medication to minimize the exposure misclassifications, nonetheless, the uncertainty 
of patients’ compliance to the prescribed regimen and the lack of prescription information may 
influence the study results. Patients with statin use at randomisation or first visit were included 
in the statin user group. We did neither record patients with prior statin use, nor new users after 
randomisation. Therefore, no cumulative statin dose could be calculated, which might be an 
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important factor, because it gives more information about the potential dose relationships and 
causality. The effect of different statins was not studied, because of the limited number of patients 
per subgroup. Differences between statins may exist since the hydrophilic statins, rosuvastatin 
and atorvastatin, have a decreased ability to penetrate cell membranes[12]. 
Another important limitation of this study is that patients were treated with the combination 
of chemotherapy, bevacizumab and cetuximab. Hypertension, a common site effect of 
bevacizumab is correlated with a better survival in CRC patients treated with bevacizumab[13]. 
A possible negative interaction between bevacizumab and cetuximab may have caused less 
hypertension in the cetuximab treated group, which contributed to the negative outcome of the 
CAIRO2 study[8]. So, for this study it means that the outcomes in the cetuximab treated group 
may have been influenced by the negative interaction between bevacizumab and cetuximab.
Obviously, PFS may be confounded by many factors. However, in our study outcomes were 
controlled for the main potential drug confounders, NSAID’s, aspirin and bisphosphonates as 
well as for prior adjuvant therapy, number of organs effected and age. Nonetheless, confounding 
from unknown variables is still possible. 
For testing a difference in effect on treatment between statin user and nonuser, PFS is the 
preferred primary endpoint. By studying PFS, a direct drug effect of statins on the cetuximab 
efficacy can be determined. A pronounced disadvantage of overall survival as an endpoint for 
this study is that this endpoint is less closely related to the drug effects. In the secondary analysis 
the use of statins in the unadjusted model was associated with a decrease of overall survival in 
the statin user group. A feasible explanation for the observed effect is that the statin users tend 
to be older and seemed to be less healthy, with a higher incidence of comorbidities then non-
statin users, a confounding by indication. In the covariate adjusted cox regression this decrease 
of survival was not significant. 
Due to the retrospective nature of this study we were not able to present data about KRAS 
prenylation levels of patients on statin therapy. In studies were the effects of statins are researched, 
data on prenylation levels of KRAS would be of great value, however at the moment a good assay to 
determine prenylation levels is lacking. To date, a number of studies have investigated statin use, 
CRC risk and clinical outcomes with inconclusive findings. Numerous studies and meta-analysis 
have investigated whether statin use reduces the risk of developing CRC[14,15]. Fewer studies 
focus on effects of statin after diagnosis during treatment [16-21]. The study of Mace et al.[16] 
showed that rectal cancer patients in the statin cohort treated with neo-adjuvant chemoradiation 
had a better response (65.7% versus 48.7%, p = 0.004) and lower median regression rate (1 
versus 2, p = 0.01). Two other studies [19,20] in patients with rectal cancer treated with neo-
adjuvant chemoradiation showed similar results indicating an association between statin use and 
response. However, in a study of Ng et al.[17], statin use during and after adjuvant chemotherapy 
among patients with stage 3 colon cancer was not associated with improved disease free survival, 
recurrent free survival or overall survival. In a prospective study of Lee et al. [18] the addition 
of simvastatin 40 mg, daily, to irinotecan, 5-fluorouracil, and leucovorin (FOLFORI) to first-line 
treatment in metastatic CRC patients showed promising antitumor activity and no additional 
adverse effects. These studies show that statin use in combination with systemic treatment 
for CRC may have some effect, but do not allow definite conclusions. However, all the above 
mentioned studies adressed the general cytotoxic effects of statins regardless of the KRAS status 
of the tumors. In our cohort we had the unique opportunity to study the effect of statins on 
cetuximab efficacy in CRC in relation to KRAS mutation status. Molecular data is warranted to 
study the exact mechanism of statins and their ability to potentiate chemotherapeutic agents. In 
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new studies with statins, molecular data from tumors and patients should be collected, this data 
help to understand the involved mechanisms.
In conclusion, the use of statins at time of diagnosis was not associated with an improved 
PFS or OS in metastatic colorectal cancer patients with a KRAS mutant tumor treated with 
combination chemotherapy bevacizumab and cetuximab.
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Safety and efficacy of the addition of 
simvastatin to cetuximab in previously 






Cetuximab is registered for use in CRC patient with RAS wild type tumours only. Simvastatin 
blocks the mevalonate pathway and thereby interferes with the post-translational modification 
(prenylation) of KRAS. We hypothesize that the activitated KRAS pathway in KRAS mutant 
tumors can be inhibited by simvastatin rendering these tumors sensitive to the EGFR inhibitor 
cetuximab. 
Methods 
A Simon two-stage, single-arm, phase II study was performed to test the efficacy and safety 
of the addition of simvastatin to cetuximab in patients with a KRAS mutation in their tumour 
who were previously treated with fluoropyrimidine, oxaliplatin and irinotecan based regimens. 
The primary endpoint of this study was to test the percentage of patients alive and free from 
progression 12.5 weeks after the first administration of cetuximab. Our hypothesis was that at 
least 40% was free from progression, comparable to, though slightly lower than in KRAS wild 
type patients.
Results 
Four of 18 included patients (22.2%) were free from progression at the primary endpoint time. 
The time to progression in these 4 patients ranged from 20.3 to 47 weeks.
Conclusion 
Based on the current study we conclude that the theoretical concept of KRAS modulation with 
simvastatin was not applicable in the clinic, as we were not able to restore sensitivity to cetuximab 
in patients harbouring a KRAS mutation.
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Introduction
Colorectal cancer (CRC) is a major healthcare issue. Each year over 940.000 patients are 
diagnosed with CRC world-wide and over 500.000 people die of this disease[1]. In patients 
with advanced or metastatic colorectal treatment with monoclonal antibodies directed against 
the epidermal growth factor receptor (EGFR), cetuximab and panitumumab are proven to be 
active after failing fluoropyrimidine, oxaliplatin and irinotecan based regimens, though only in 
patients with tumours without a mutation in the KRAS[2;3] or more recently RAS gene[4]. At 
time of design of this study, patients with a KRAS mutation in their tumour were left with no 
therapeutic options after failing conventional therapy. This led to the question whether increased 
activation of KRAS signaling by KRAS mutations can be modulated, thereby making KRAS 
mutated tumours sensitive to EGFR inhibitor therapy. One possible target for modulation is the 
mevalonate pathway, as we have previously discussed[5].
The mevalonate pathway is a metabolic cascade with various end-products including 
cholesterol. Other end-products are farnesylated and geranylgeranylated proteins (C15 and C17), 
both essential for posttranslational prenylation of the RAS protein and its association with the 
cytoplasmic membrane, and thereby activation of the RAS protein (Figure 1). By using HMG-
CoA reductase inhibitors not only the synthesis of cholesterol is inhibited, but also the formation 
of C15 and C17, thereby inhibiting posttranslational modification of RAS[5;6]. By blocking the 
mevalonate pathway in CRC patients with KRAS mutated tumours, the activated KRAS pathway 
might be inhibited. This would theoretically lead to increased sensitivity to cetuximab, potentially 
comparable to tumours with wild type KRAS.
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Figure 1: Mevalonate pathway
 
 
This single-arm, phase II study was designed to test the safety and efficacy of the addition of 
simvastatin to cetuximab in patients with a KRAS mutation in their tumour who were previously 
treated with fluoropyrimidine, oxaliplatin and irinotecan based regimens.
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Methods
Patients 
Eligible patients had advanced or metastatic colorectal cancer with a mutation in codon 12, 13 
or 61 of the KRAS gene (either on tissue of the primary tumour or of a metastasis), after failing 
fluoropyrimidine, oxaliplatin and irinotecan based regimens, or after failure of oxaliplatin based 
therapy in patients who cannot be treated with irinotecan. In case of progressive disease within 6 
months after start of adjuvant fluoropyrimidine, oxaliplatin, and irinotecan containing regimens 
the adjuvant therapy was considered to be treatment for metastatic disease.
Other eligibility criteria included age 18 years or older, World Health Organisation (WHO) 
performance score of 0 to 2 and progression of disease in the past three months prior to 
inclusion. Exclusion criteria included symptomatic brain metastases, previous treatment with 
EGFR inhibitors, history of toxicity during statin use and another malignancy during the past 
four years (with the exception of non-melanoma skin cancer and adequately treated pre-invasive 
carcinoma of the cervix).
The study protocol was approved by the Ethics Committees of all participating hospitals. 
Written informed consent was obtained prior to any study-related interventions.
 Study design 
This phase II, single-arm, multi-center study was performed using a Simon two-stage design[7]. 
In the first stage, 15 patients were included, followed by an interim analysis. Results of this 
analysis would determine whether the combination of simvastatin and cetuximab may have 
clinical benefit in this group of CRC patients, thus justifying the second stage and including up 
to 41 patients. If the first stage would suggest that this combination does not indicate clinical 
benefit, no additional patients would be exposed to this combination.
Treatment schedule
Cetuximab was first administered at least one week after start of simvastatin therapy. The initial 
cetuximab dose was 400 mg/m² (over 120 minutes) with subsequent weekly infusions of 250 mg/
m² (over 60 minutes). Pretreatment with an antihistamine and a corticosteroid was mandatory 
before the first infusion of cetuximab and recommended for all subsequent infusions. 
Simvastatin 80 mg orally once daily was started at start of study participation and continued 
throughout the entire study. This dose was chosen taken into consideration the need for continuous 
administration of the statin during the entire study, inhibitory effect on the mevalonate pathway 
and tolerability. Statins in cancer therapy have been studied in clinical trials in solid[8-18] and 
haematologic [19-21] malignancies, both as monotherapy as well as additional to chemotherapy. 
Statin doses from 20 mg/day up to 35 mg/kg/day were used, with only continuous use of statins 
when dosed at a maximum of 80 mg/day. Since the aim of this study is to modulate KRAS during 
the entire treatment with cetuximab and therefore a continuous exposure to simvastatin is 
needed, a dose of 80 mg/day was selected in order to obtain maximum effect while minimizing 
the risk of toxicity. Patients who were already using statins prior to inclusion had to switch to 
simvastatin in the above mentioned dose.
Treatment was continued until progression of disease, clinical signs of progression according 
to the investigators assessment, unacceptable toxicity or cetuximab toxicity requiring withholding 
of more than two subsequent infusions.
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Tumour response was every six weeks using CT-scans and according to Response Evaluation 
Criteria In Solid Tumors (RECIST) version 1.1. Scans of patients free from progression at time 
of primary endpoint were centrally reviewed. All patients were followed for survival once every 
3 months after termination of study participation. All patients were assessed for toxicity prior to 
every administration of cetuximab.
Endpoints
Primary objective was to test the percentage of patients with KRAS mutant advanced or 
metastatic colorectal cancer alive and free from progression and alive at 12.5 weeks after the first 
administration of cetuximab in combination with simvastatin. Our hypothesis was that at least 
40% of patients was free from progression, comparable to though slightly lower than in KRAS 
wild type patients[2]. 
Secondary objectives were to investigate overall survival (OS), objective response rate 
(ORR), progression free survival (PFS), and safety of simvastatin combined with cetuximab in 
this population and to evaluate the correlation between skin toxicity and response to treatment. 
Exploratory endpoints were to investigate the role of cholesterol as a possible biomarker 
during this treatment and whether PIK3CA status correlate with response to cetuximab in this 
population.
Mutational analysis
KRAS mutational status was reconfirmed centrally, testing for the seven most frequent mutations 
in codon 12 and 13 as described in detail elsewhere[22]. In addition, we tested for the three 
most common mutation in the PIK3CA gene; in exon 9 (c.1624G>A (p.E542K) and c.1633G>A 
(pE545K)) and exon 20 (c.3140A>G (p.H1047R). Though KRAS and BRAF mutations are known 
to be mutually exclusive[23], we did test for the activating hotspot mutation p.V600E. 
Statistics
Sample size was chosen based on previous published data of CRC patients with KRAS wild 
type tumours treated with cetuximab[2], aiming for a at least six out of 15 patients free from 
progression at 12.5 weeks after start of cetuximab treatment in patients with KRAS mutant type 
tumours (i.e., slightly lower than the effect in KRAS wild type patients). Combined with an alpha 
of 0.05 and a power of 0.80, an interim size of 15 and a total sample size of 46 patients were 
required. An interim analysis was to be performed after the inclusion of 15 evaluable patients. 
Only when at least 40% (i.e. 6 patients) were free from progression at the 12.5 weeks, another 31 
patients would be enrolled during the second stage of the study. 
Results
Patients
During the first stage of the study 18 instead of 15 patients were enrolled to account for patients 
that were thought to unevaluable for the primary endpoint. Baseline characteristics are listed in 
Table 1. Fifteen patients had previously been receiving two lines of chemotherapy, two patients 
were only treated with oxaliplatin/5FU based therapy prior to inclusion and 1 patient had received 
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three lines of chemotherapy (oxaliplatin and irinotecan based therapy and regorafenib during 
participation in a different trial). None of the patients were using statins prior to inclusion.
Table 2 shows type of KRAS mutation per patient, along with PIK3CA mutational status.
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Prior surgery – n (%) 13 (72)
Prior radiotherapy – n (%) 4 (22)
Table 2: KRAS and PIK3CA mutational status per patient
Study number KRAS mutation PIK3CA mutational status
1 G12D Wild type
2 G12V Wild type
3 G12V Wild type
4 G12C Wild type
5 G12V Wild type
6 G12S Wild type
7 missing Missing
8 G12V Wild type
9 G13D Wild type
10 G13D Wild type
11 G12D Wild type
12 G12D Wild type
13 missing Missing
14 G12V Wild type
15 G12A Wild type
16 G12A Wild type
17 G13D Mutation in exon 9




Four of 18 patients were free from progression at the primary endpoint time, therefore the 
percentage of patients alive and free from progression 12.5 weeks after the first administration of 
cetuximab was 22%. The time to progression in these four patients ranged from 20.3 to 47 weeks. 
Drug exposure to simvastatin and cetuximab was equal for all patients since none of the patients 
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Figure 2 shows progression free (panel A) and overall survival (panel B). Median progression 
free survival was nine weeks (mean 12.9 weeks, range 3.9 - 47 weeks). Median overall survival 
was 31.5 weeks (mean 36.3, range 8-138.1). Objective response rate was 6% (partial remission in 
one patient). A true relation between skin toxicity and efficacy of treatment was not observed in 
this study though this may (partly) be due to the low number of patients and due to the improved 
knowledge of the efficacy of pre-emptive skin toxicity management.
Safety
Main symptoms and adverse events reported on study reported were fatigue (n=11), acne (n=10) 
and rash (n=6). Myopathy was not reported. Three patients had elevation of creatine kinase 
(CK) levels on study (grade 4 in one patient). Table 3 shows the most frequent reported adverse 
events. Skin toxicity occurred in 10 patients; the worst grade of acneiform rash was grade 3 in 
one patient, grade 2 in four patients and grade 1 in the remaining five patients. One patient 
experienced a severe (i.e. grade 3) allergic reaction during the first infusion of cetuximab. This 
was the only grade 3 infusion reaction reported during the entire study, and this patient did 
not experience any further reactions while on study. Hypomagnesaemia was reported in four 
patients, no cases of hypocalcaemia were reported.
Table 3: Adverse events occurring in > 10%
Event Any grade Grade 3-4
Fatigue 11 (61%) 1 (6%)
Acneiform rash 10 (56%) 1 (6%)
Anemia 9 (50%) -
Rash (not acneiform) 6 (33%) 1 (6%)
Tumour-related pain 6 (33%) 1 (6%)
Pruritis 5 (28%) -
Nausea 5 (28%) -
Dyspnea 4 (22%) -
Hypomagnesaemia 4 (22%) -
Creatine kinase elevation 3 (17%) 1 (6%)
Constipation 3 (17%) -
Fever 2 (11%) -
Infusion related reaction 2 (11%) 1 (6%)
Thrombocytopenia 2 (11%) -
Weight loss 2 (11%) -
Thrombosis 2 (11%) 1 (6%)
 
One of the serious adverse events did precede the death of a participant. Upon the scheduled 
laboratory examination severe elevation of liver enzymes were observed soon after start of study 
medication. Rhabdomyolysis due to simvastatin was considered, (though on study CK levels 
were below 3.000 U/l) and so was progression of liver metastases with impaired liver function. 
Study medication was interrupted immediately, however the patient’s situation did not improve 
and it was decided to terminate study participation permanently. Specific SNPs associated 
with increased risk of statin-induced myopathy (i.e. SLCO1B1 variants[24]) were considered 
though none were identified in this patient. The patient deceased few weeks later. Post-mortem 




Serum cholesterol was measured in all patients at baseline and in 15 patients on study. All 
showed cholesterol reduction, ranging from a maximum reduction of 0.8% to 64.4%. Cholesterol 
reduction on study did not differ between patients free from progression at time of primary 
endpoint compared to those who were not (mean reduction 37.1% versus 30.5%, p-value = 0.55). 
The percentage of cholesterol reduction did not correlate with progression free survival.
Tumour tissue of 15 patients was available for central review. Table 3 shows mutational status 
of KRAS and PIK3CA per patient. Thirteen patients had a mutation in codon 12 (most often 
G12D and G12V) and three in codon 13. A mutation in the PIK3CA gene was detected in 2 
patients (both exon 9). Of the four patients responding to treatment, 3 had a KRAS mutation 
in codon 12 and one had a PIK3CA mutation. As expected in patients with a KRAS mutation in 
their tumour, all patients were BRAF wild type.
Discussion
To our knowledge, this is the first clinical trial testing the addition of simvastatin to cetuximab 
monotherapy in CRC patients harbouring a KRAS mutation in tumour tissue as an attempt 
to restore cetuximab sensitivity. While it was remarkable to notice a durable progression free 
survival in four patients, the interim analysis showed that the predefined criteria to proceed to 
the second stage of this study were not reached. Therefore, the current study suggests that high 
dose simvastatin does not render cetuximab sensitivity in KRAS mutant CRC.
Statines are one of several potential agents to modulate KRAS signaling, as we have previously 
reviewed[5]. The current study is not the first to hypothesize on statins and their inhibitory effect 
on the activity of RAS and its downstream pathway. However, all but one previous reports include 
only preclinical data. Lovastatin showed to inhibit RAS activation in KRAS transformed thyroid 
cells through inhibition of its farnesylation, and thereby inhibiting activity of the downstream 
pathway[25]. Furthermore, lovastatin and simvastatin inhibit downstream activity in breast 
cells with mutated HRAS, known to induce an invasive phenotype, possibly by inhibiting 
membrane localization of HRAS. The effect was reversed when adding farnesyl pyrophosphate, 
indicating the effect was related to prenylation of RAS[26]. More recently, simvastatin was 
shown to restore cetuximab resistance in vitro and in vivo[27]. Based on these results, one might 
wonder whether the negative outcome of the current study would have been different if using 
higher doses of simvastatin. As mentioned above, statin doses up to 35 mg/kg/day have been 
prescribed in clinical trials, though higher doses were not used continuously as was essential 
in the current design. Preclinical data showed a significant reduction in cell growth of KRAS 
mutant CRC cell lines using 0.2 μM simvastatin, the equivalent of 2mg/kg/day in humans[27]. 
Moreover, in cardiovascular disease the registered dose of 80 mg of simvastatin is significantly 
lowers cholesterol serum levels. It is reasonable that this dose will also affect the formation of the 
C15 and C17 groups and subsequently the prenylation of the KRAS protein. Furthermore, we 
question whether higher doses will be feasible in terms of safety.
A recent study of Lee et al tested the efficacy of the addition of the same dose of simvastatin 
(i.e. 80mg once daily) to cetuximab and irinotecan in KRAS mutant CRC patients failing prior 
oxaliplatin, fluoropyrimidine and irinotecan based therapy[28]. The initially reported PFS 
and OS (median 7.6 months and 12.8 months respectively) were considerably higher than 
historical results in chemotherapy refractory CRC patients with KRAS mutated tumours[29] 
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and chemotherapy refractory CRC patients in general[30-32]. Moreover, these results were in 
contrast with our findings and the authors concluded that simvastatin may overcome cetuximab 
resistance in patients with KRAS mutant tumours. However, a recent erratum published by this 
group showed that initial survival data were incorrect[33]. The corrected PFS and OS are in 
line with our results, providing no evidence for a modulating effect of simvastatin on the KRAS 
mutant phenotype. 
The majority of patients had a KRAS mutation in codon 12 and only 3 in codon 13. It has 
been reported that tumours harbouring a G13D mutation in the KRAS gene might be sensitive 
to EGFR-inhibitors[34]. Moreover, none of our patients had a PIK3CA mutation in exon 20. 
Mutations in exon 20 of the PIK3CA gene might also be more likely to be sensitive to EGFR-
inhibitors, contrary to mutations in exon 9[35]. However, while the number of patients in our 
study is low, of the four patients who were free from progression at time of the primary endpoint 
only one patients had a G13D mutation in the KRAS gene and none had a PIK3CA mutation in 
exon 20. 
While one patient developed impaired liver function, it remains unclear whether this was 
related to simvastatin. Nonetheless, CK levels were clearly increased in this particular patient. 
However, none of the other patients reported statin related adverse events (e.g. myopathy) and 
CK levels were only mildly elevated in two patients. There was no need for dose reduction. 
Overall, simvastatin 80 mg once daily was considered well tolerated in the current population.
Conclusion
Based on the current study we conclude that the concept of KRAS modulation with simvastatin 
was not applicable in the clinic. Other strategies are needed for CRC patients with tumours 
harbouring a KRAS mutation who failed standard therapy. Recently regorafenib was registered 
for CRC patients failing standard therapy (including EGFR inhibitors if wild type KRAS), but the 
gain in survival is limited to 6 weeks[30]. Better treatment strategies are needed for this patient 
population. 
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Safety and efficacy of the addition 
of simvastatin to panitumumab in 
previously treated KRAS mutant 





Panitumumab has proven efficacy in patients with metastatic or locally advanced colorectal 
cancer patients provided they have no activating KRAS mutation in their tumour. Simvastatin 
blocks the mevalonate pathway and thereby interferes with the post-translational modification 
of KRAS. We hypothesize that the activity of the RAS induced pathway in patients with a 
KRAS mutation might be inhibited by simvastatin. This would theoretically result in increased 
sensitivity to panitumumab, potentially comparable to tumours with wild type KRAS.
Methods 
A Simon two-stage design single-arm, phase II study was designed to test the safety and efficacy of 
the addition of simvastatin to panitumumab in colorectal cancer patients with a KRAS mutation 
after failing fluoropyrimidine, oxaliplatin and irinotecan based therapy. The primary endpoint 
of this study was the proportion of patients alive and free from progression 11 weeks after the 
first administration of panitumumab, aiming for at least 40% which is comparable to though 
slightly lower than in KRAS wilde-type patients in this setting. If this 40% was reached then the 
study would continue into the second step up to 46 patients. Explorative correlative analysis for 
mutations in the KRAS and related pathways was performed.
Results 
One of 14 patients was free from progression at the primary endpoint time. Median progression 
free survival was 8.4 weeks, median overall survival status was 19.6 weeks. 
Conclusion 
We conclude that the concept of mutant KRAS phenotype expression modulation with 
simvastatin was not applicable in the clinic.
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Introduction
The epidermal growth factor receptor (EGFR) inhibitors panitumumab and cetuximab have 
proven efficacy in third-line treatment of colorectal cancer (CRC) patients failing 5-FU, 
oxaliplatin and irinotecan based regimens [1;2], but only in patients with tumours not harbouring 
an activating KRAS mutation in codon 12, 13 or 61 [3-5] or, more recently published, several 
other RAS mutations [6]. At the time of design of this study the available literature showed that 
KRAS mutations are found in tumour tissue of 40% of CRC patients, at least 90% located on 
codon 12 or 13 of the KRAS gene [4]. Patients harbouring these mutations in their tumour were 
left with little therapeutic options after failing standard therapy. This raised the question whether 
KRAS mutations can be modulated, thereby making KRAS mutated tumours sensitive to EGFR 
inhibitor therapy. The possible target for the simvastatin modulation is the mevalonate pathway, 
as we have previously discussed [7].
Statins (HMG-CoA-reductase inhibitors) inhibit cholesterol synthesis by inhibiting the 
mevalonate pathway, a metabolic cascade also responsible for syntheses of farnesylated and 
geranylgeranylated proteins (C15 and C17), both essential for post-translation activation of 
the KRAS protein [8]. As statins also inhibit the synthesis of C15 and C17, they may inhibit 
post-translational activation of RAS proteins. Therefore, statins may inhibit the expression of 
the mutant KRAS phenotype and normalize the phenotype into KRAS wild type, rendering 
sensitivity to panitumumab.
This single-arm, multicenter phase II study was designed to test safety and efficacy of the 
addition of simvastatin to panitumumab in previously treated CRC patients with a KRAS 
mutation in their tumour.
Methods
Patients 
Eligible patients had advanced or metastatic colorectal cancer with a mutation in codon 12, 13 
or 61 of the KRAS gene (either on tissue of the primary tumour or of a metastasis), after failure 
of fluoropyrimidine, oxaliplatin and irinotecan based regimens, or after failure of oxaliplatin 
therapy and unable to tolerate irinotecan. In patients with progressive disease within six months 
after start of adjuvant therapy, these therapies were considered to be treatment for metastatic 
disease.
Other eligibility criteria included: age 18 years or older, World Health Organisation (WHO) 
performance score of 0 to 2 and progression of disease in the three months prior to inclusion. 
Exclusion criteria included symptomatic brain metastases, previous treatment with EGFR 
inhibitors, history of toxicity during statin use or an other malignancy during the past four years 
(with the exception of non-melanoma skin cancer and adequately treated pre-invasive carcinoma 
of the cervix).
The study protocol was approved by the Ethics Committees of all participating hospitals 
and all study procedures were in accordance with the 1964 Helsinki declaration and its later 





Panitumumab 6 mg/kg was administered intravenously once every two weeks. The first 
administration was scheduled at least one week after start of simvastatin. Simvastatin 80 mg 
once daily was started at baseline and continued throughout entire study participations, though 
dose reductions or temporary interruptions were allowed in case of toxicity. This starting 
dose of simvastatin was chosen for the following reasons: inhibitory effect on the mevalonate 
pathway (and not high dose antitumour effect by itself), tolerability and the need for continuous 
administration of the statin during the entire study. Statins in cancer therapy have been studied 
in clinical trials in solid [9-19] and haematologic [20-22] malignancies, both as monotherapy 
as well as additional to standard therapy. Statin doses from 20 mg/day up to 35 mg/kg/day were 
used in various intermittent schedules. In continuous dosing schedules, simvastatin was used 
at a maximum of 80mg/day. The aim of this study was to modulate KRAS during the entire 
treatment with panitumumab, therefore a continuous exposure to simvastatin was needed and a 
dose of 80 mg/day was selected in order to obtain maximum effect while minimizing the risk of 
toxicity. Patients who were already using statins prior to inclusion had to switch to simvastatin 
Treatment was continued until progression of disease according to Response Evaluation Criteria 
In Solid Tumors (RECIST) version 1.1, clinical signs of progression according to the investigators 
assessment, unacceptable toxicity, signs of rhabdomyolysis or panitumumab toxicity requiring 
interruption of treatment.
Tumour response was measured seven weeks after baseline and every two cycles thereafter 
using CT-scans and according to RECIST version 1.1. These intervals were based on historical 
data on PFS of KRAS wild type colorectal cancer patients treated with panitumumab [3]. Scans 
of patients free from progression at the time of primary endpoint were centrally reviewed. 
All patients were followed for survival once every three months after termination of study 
participation. Adverse events were monitored on an ongoing basis per cycle and toxic effects 
were categorized using the NCI Common Terminology Criteria for Adverse Events (CTCAE), 
Version 3.0.
Endpoints
Primary endpoint was the proportion of patients alive and free from progression at 11 weeks 
after the first administration of panitumumab in combination with simvastatin. Our hypothesis 
was that at least 40% of patients would be free from progression at 11 weeks, comparable to 
though slightly lower than the proportion of KRAS wild type patients that remains free from 
progression at 11 weeks when treated with panitumumab [3]. 
Secondary endpoints were overall survival (OS), objective response rate (ORR), progression 
free survival (PFS), and safety of simvastatin combined with panitumumab in this population 
and to evaluate the correlation between skin toxicity and response to treatment. Exploratory 
endpoints were to investigate the role of cholesterol as a possible biomarker during this treatment 
and whether PIK3CA status correlates with response to panitumumab in this population.
Mutational analysis
KRAS mutational status was reconfirmed centrally, testing for the seven most frequent mutations 
in codon 12 and 13 as described in detail elsewhere[23]. In addition, we tested for the three 
most common mutation in the PIK3CA gene; in exon 9 (c.1624G>A (p.E542K) and c.1633G>A 
(pE545K)) and exon 20 (c.3140A>G (p.H1047R). Though KRAS and BRAF mutations are known 
to be mutually exclusive[24], all tissue was tested for the activating hotspot mutation p.V600E. 
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Design and statistics
This phase II, single-arm, multi-center study was performed using a Simon two-stage design [25]. 
In the first stage, 15 patients were included, after which an interim analysis was performed. Results 
of this analysis would determine whether the combination of simvastatin and panitumumab may 
have clinical benefit in this group of CRC patients, thus justifying the second stage up to 46 
patients in total.
The sample size was chosen based on previously published data of CRC patients with KRAS 
wild type tumours treated with panitumumab [3], aiming for at least 6 out of 15 patients free from 
progression at 11 weeks after start of combination panitumumab and simvastatin treatment in 
patients with KRAS mutant type tumours. Combined with an alpha of 0.05 and a power of 0.80, 
an interim size of 15 and a total sample size of 46 patients were required. An interim analysis 
was to be performed after the inclusion of 15 evaluable patients. Only when at least 40% (i.e. 
six patients) were free from progression at the 11 weeks, another 31 patients would be enrolled 
during the second stage of the study. 
Results
Patients
From April 2010 to May 2012, 17 patients were included. Notably, 17 instead of 15 patients were 
included, due to the fact that two patients were considered to be unevaluable (both showed clinical 
signs of progression prior to the first infusion of panitumumab ). However, after review, three 
instead of two patients were unevaluable (Figure 1). The third unevaluable patient had a second 
malignancy which was first discovered at the baseline CT-scan. As none of the three unevaluable 
patients received panitumumab, all three were excluded in the efficacy and safety analysis. Baseline 
characteristics of the remaining 14 patients are listed in Table 1. One patient only received 
oxaliplatin/5FU based chemotherapy prior to study participation. None were receiving any kind 
of statin prior to study participation. Table 2 shows type of KRAS mutation per patient, along with 
PIK3CA mutational status. Tumour tissue was available in all but one patient. Two patients had a 
PIK3CA mutation on tumour tissue, one located in exon 20 and one in exon 9. Eleven patients had 
a KRAS codon 12 mutant tumour and two patients had a KRAS codon 13 mutant tumour. 
Efficacy
One study participant was free from progression at the primary endpoint time. The percentage of 
patients alive and free from progression 11 weeks after the first administration of panitumumab 
is therefore 7%. The predefined criteria to proceed to the second stage of the study were not met, 
therefore no further patients were included. Time to progression in this particular patient was 
17 weeks, median time to progression was 8.4 weeks (mean 8.7, range 5-17, Figure 2 panel A). 
Median overall survival was 19.6 weeks (mean 24.2, range 8.3-71.1, Figure 2 panel B). Objective 
response rate was 0% as none of the patients had a (partial) remission. Analysis of a correlation 
between skin toxicity and efficacy was not feasible due to absence of responders. 
Exposure to panitumumab was equal in all patients; none required dose reductions or 
delays. Two patients needed 50% dose reduction of simvastatin, both after the second infusion 
of panitumumab. Reason for dose reduction was elevation of liver enzymes in one patient. In the 
other patient reason for dose reduction was not specified, though liver enzymes were stable in 
this specific patient and myalgia was not reported. 
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Figure 1: Flow chart of the inclusion of patients
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Table 2: Mutational status per patient
Study nr KRAS PIK3CA
1 G12V Wild type
2 G12D Wild type
3 G12C Wild type
4 G12V Wild type
5 G12D Wild type
7 G12V Wild type
8 G12A Wild type
9 G12A Wild type
10 G12V Mutation in exon 20
11 G12D Wild type
13 G13D Mutation in exon 9
14 G13D Wild type


















Figure 2a: Kaplan meier plot for 
progression free survival in weeks 
of CRC patient treated with 80 


















Figure 2b: Kaplan meier plot for 
overall survival in weeks of CRC 
patient treated with 80 mg of 





The most frequently reported adverse events on study were fatigue (n=10), anemia (n=9) and 
hypomagnesaemia (n=9). The incidence of severe adverse events is provided in Table 3. Skin 
toxicity occurred in 10 patients. Acneiform rash was reported in seven patients, none had grade 
3 acneiform rash, though one case of grade 3 folliculitis was reported. Myopathy occurred in 
three patients. Grade 3 myopathy was reported in one patient and the patient terminated study 
participation for this reason. Elevation of CK was reported in all three patients with myopathy 
(up to 3917U/l in one patient) and in two additional patients. 










To the best of our knowledge this is the first clinical trial of combined treatment with simvastatin 
and panitumumab in CRC patients with a KRAS mutation in tumour tissue, testing the theoretical 
concept of KRAS modulation by statins. As only one out of 14 patients was alive and free from 
progression at time of the primary endpoint, study enrolment was terminated after the first stage 
of the study and it was concluded that simvastatin does not render sensitivity to panitumumab 
in this specific population.
The current study is not the first to hypothesize on statins and their inhibitory effect on the activity 
of RAS and its downstream pathway. However, all but one previous report are on preclinical 
research. Lovastatin was shown to inhibit RAS activation in KRAS transformed thyroid cells 
through inhibition of its farnesylation, and thereby inhibiting activity of the downstream pathway 
[26]. Furthermore, it was shown that lovastatin and simvastatin inhibit downstream activity in 
breast cells with mutated HRAS, known to induce an invasive phenotype, possibly by inhibiting 
membrane localization of HRAS. The effect was reversed by farnesyl pyrophosphate, indicating 
the effect was related to prenylation of RAS [27]. More recently, simvastatin was shown to restore 
cetuximab resistance in vitro and in vivo [28]. Based on these results, it may be questioned if a 
higher dose of simvastatin would have been necessary to overrule KRAS mutation and render 
sensitivity to EGFR inhibitor therapy. As mentioned above, statin doses up to 35mg/kg/day 
have been prescribed in clinical trials, though higher doses were not used continuously as was 
essential in the current design. Preclinical data research showed a significant reduction in cell 
growth of KRAS mutant CRC cell lines using 0.2 μM simvastatin, the equivalent of 2 mg/kg/day 
in humans [28]. Moreover, in cardiovascular disease the registered dose of 80 mg of simvastatin 
is significantly lowerings cholesterol serum levels. It is reasonableto assume that this dose will 
also affect the formation of the C15 and C17 groups and subsequently the prenylation of the 
KRAS protein. Furthermore, we question whether higher doses will be feasible in terms of safety.
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The lack of effect in the current study is in striking contrast with the original reported data by 
Lee et al [29], testing the addition of simvastatin 40mg once daily to third-line therapy with 
cetuximab plus irinotecan in CRC patients harbouring a KRAS mutation. Their original report 
showed indeed a low response rate ((one out of 52 patients had a partial remission), however 
PFS was 7.6 months, which is even higher than historical results of third-line cetuximab plus 
irinotecan in KRAS wild type CRC patients [30;31]. However, in a recent erratum Lee et al [32] 
reported corrected measurements of PFS in their population. Corrected mean PFS was 3.7 
months (range 2.1-5.3), significantly lower than previous reports of cetuximab plus irinotecan as 
third-line therapy in KRAS wild type [30;31]. In summary, both our study as well as the study by 
Lee et al show that simvastatin does not render sensitivity to EGFR inhibitor therapy. 
Mutational status of PIK3CA is also related to response to EGFR inhibitor based therapy. The 
majority of PIK3CA mutations are located in exon 9 and exon 20, and those mutations may occur 
in patients with or without KRAS mutation in tumour tissue. Only PIK3CA mutations in codon 
20 are associated with lower ORR and PFS [4]. If statins would be able to induce a KRAS wild 
type phenotype in our population, a high incidence of PIK3CA mutations might still lead to low 
PFS. However, since only two patients harboured a PIK3CA mutation (one in exon 9 and one in 
exon 20), this is not likely to (partly) explain the results of the current study. 
Toxicity of this dose of simvastatin in CRC patients failing standard chemotherapy was 
relatively mild, with only two patients in need for dose reduction and only one patients expe-
riencing severe myopathy. Panitumumab was also well tolerated, in line with previous data of 
panitumumab as third-line therapy [2].
Conclusion
The present study showed that simvastatin 80 once daily does not render sensitivity to 
panitumumab in CRC patients with a KRAS mutation failing oxaliplatin, 5-FU and irinotecan 
based therapy. The theoretical concept of KRAS modulation using statins does not seem feasible 
in the clinic. Recently, regorafenib was registered for these patients (and for KRAS wild type 
patients after failing third-line therapy with an EGFR inhibitor), however PFS gain is limited 
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The use of cetuximab in metastatic colorectal cancer (CRC) is limited to patients with wild type 
KRAS tumors and more recently to RAS wild type tumors only. Antibody-dependent cellular 
cytotoxicity (ADCC), mediated by the Fc gamma receptor (FCGR) is assumed to be an important 
mechanism for induction of tumor cell death by cetuximab. Several studies explored the role of 
FCGR3A (rs396991) genetic polymorphism in cetuximab efficacy in mCRC patients, but the 
results from these studies are discordant. 
Method
An individual patient data meta-analysis was performed, to better understand the effect of 
FCGR3A FF versus non FF (FV and VV) polymorphism on progression free survival (PFS) and 
overall survival (OS) in patients with KRAS mutant or wild type metastatic CRC, treated with 
cetuximab. Three studies were included in this meta-analysis. 
Results 
The hazard ratio (HR) for the primary endpoint progression free survival for FCGR3A non FF, 
adjusted for KRAS and the interaction between FCGR3A and KRAS was equal to 1.07 (95% 
confidence interval 0.89 - 1.29, p = 0.45). For overall survival, the HR for FCGR3A non FF, 
adjusted for KRAS and the interaction between FCGR3A and KRAS was equal to 0.91 (95% 
confidence interval 0.77 - 1.07). 
Conclusion
The results of the present analysis suggest that FCGR3A rs396991 is not associated with 
progression free or overall survival in cetuximab treated mCRC patients.
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Introduction
Cetuximab is an IgG1-type chimeric monoclonal antibody (MoAb) that targets the epidermal 
growth factor receptor (EGFR). Cetuximab is mainly used for treatment of metastatic colorectal 
cancer. Blocking of EGFR results in decreased proliferation, cell survival and angiogenesis. 
However, about 40% of colorectal cancers harbor a mutation in KRAS and these tumors do not 
respond to anti-EGFR therapy[1-3]. For this reason, the use of cetuximab is limited to patients 
with wild type KRAS tumors and more recently to patients with RAS wild type tumors only[4]. 
Antibody-dependent cellular cytotoxicity (ADCC), mediated by the Fc gamma receptor 
(FCGR) is assumed to be an important mechanism for induction of tumor cell death by 
cetuximab[5]. MoAbs are molecules of the IgG class and have an antigen-binding fragment (Fab) 
and a constant fragment (Fc). Fc gamma receptors (FCGRs) are expressed on immune effector 
cells, such as macrophages and natural killer lymphocytes. ADCC is induced when FCGRs bind 
to the monoclonal Fc fragment, since this interaction leads to the activation and degranulation 
of the effector cells and the subsequent lysis of the tumor[6]. 
Several germline single nucleotide polymorphisms (SNP) in the FCGR gene have been 
identified that confer a different binding affinity of the FCGR to the Fc fragment of the MoAb. 
The polymorphism in the Fc gamma receptor 3A gene (FCGR3A) c.818A>C results in a change 
of phenylalanine (F) to valine (V) at position 158 (rs396991)[6,7]. The C allele coding for valine 
of FCGR3A has a much higher affinity for binding to Fc than the wild type A allele coding 
for phenlyalanine. Importantly, the V phenotype has been related with a more extensive IgG1-
induced ADCC[8,9]. Several studies, especially in large B-cell and follicular lymphoma patients 
treated with the MoAb rituximab, show a better clinical outcome for patients with FCGR3A VV 
phenotype, a finding that might be explained by the higher binding affinity conferred by this V 
phenotype[5,10-12]. 
The possible advantage of FCGR3A VV phenotype is less clear in mCRC patients treated 
with cetuximab. Indeed, the results from several studies investigating the association between 
FCGR3A genotype and cetuximab efficacy in mCRC patients are discordant (Table 1). A total of 13 
published studies have investigated the association between FCGR3A and response, progression 
free or overall survival in mCRC patients treated with cetuximab. Seven studies[13-19] did not 
find any significant association between FCGR3A and outcome. The studies by Bibeau et al.[20] 
and Calemma et al.[21] reported that patients with the FCGR3A VV phenotype had a longer PFS. 
In contrast, four other studies reported a higher likelihood of cetuximab induced progression free 
or overall survival for patients with the FCGR3A F phenotype. In the study of Zhang et al.[22] a 
significantly higher response rate (RR) was seen in cetuximab plus bevacizumab treated patients 
with the FF group (RR = 56%) compared to FV (RR = 25%) and VV (RR = 8%) phenotypes. 
Dahan et al. [23] (58 patients) reported a decreased overall survival for patients with the FCGR3A 
VV phenotype whereas Pander et al. showed that the C allele coding for valine was associated 
with a shorter progression free survival[24]. Finally, a small study performed by Zhang et al. in 
2007 with only 39 mCRC patients showed that those with the F-containing phenotype (FF or FV) 
had a longer PFS [31]. These conflicting results could be explained by a limited sample size of the 
different studies, genotyping errors (distribution of the genotypes is not always consistent with 
the Hardy-Weinberg equilibrium)[25-26] and different clinical scenarios. 
As mentioned, most studies did have some drawbacks regarding the number of patients per 
study. The studies of Bibeau et al.[27], Zhang et al.[22] and Park et al.[28] reported genotype 
distributions of FCGR3A which deviated from Hardy-Weinberg equilibrium. Some of these 
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studies reported an altered outcome for the different FCGR3A genotypes, however, deviation 
from the Hardy-Weinberg equilibrium raises concerns in interpreting the outcome of these 
studies. All studies conducted retrospective analysis and positive/significant associations were 
found in relatively small patient cohorts, ranging from 32 to 270 patients. In these small studies 
many associations may have been studied and due to multiplicity, false positive associations may 
have occurred.
In an earlier study of our research group, the study of Pander et al.[24], we showed that the 
V-phenotype was associated with worse progression. In addition, in an in vitro study we showed 
that an extensive binding of FCGR3A with the C allele coding for valine, expressed by type 2 
macrophages, resulted in the release of tumor promoting factors[29]. This effect of the FCGR3A 
genotype appeared independent of the KRAS mutation status of the tumor[24]. This preclinical 
finding, resulting in extensive release of tumor promoting factors after extensive binding by 
the C allele coding for V, was the basis to further investigate the association between FCGR3A 
polymorphisms, KRAS mutational status and survival. A dominant model was used to study 
the differences between FCGR3A wild type FF versus FCGR3A heterozygous mutant FV plus 
homozygous mutant VV. Interestingly, in both our preclinical study and the CAIRO2 study an 
effect of FCGR3A was seen independent of KRAS mutational status. Interestingly, the effect of 
the FCGR3A polymorphism was substantial and in patients with a KRAS mutant tumor and a 
favourable FCGR3A polymorphism survival was comparable to patients with a KRAS wild type 
tumor but unfavourable FCGR3A polymorphism. For this reason, we aimed to study the effect 
of the FCGR3A (rs396991) polymorphism in patients with KRAS wild type and mutant CRC 
despite the fact that cetuximab is nowadays only used in RAS wild type patients. Consequently, 
for our meta-analysis we selected studies in which patients were included with KRAS mutant and 
wild type tumors, performed at the time when the use of cetuximab was not yet restricted to (K)
RAS wild type tumors. 
We conducted an individual patient data meta-analysis combining 1,301 patients from 
three independent studies, to study and FCGR3A FF versus non FF (FV and VV) phenotypes 
on the progression free survival (PFS) and overall survival (OS) of metastatic colorectal cancer 
in patients with a KRAS mutant or wild type tumors treated with cetuximab. The other studies 
were excluded due to unknown KRAS status, KRAS wild type patients only, genotyping method, 
missing survival data or inability to provide the data.
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Table 1: Overview of previous published studies, which studied the association between 
FCGR3A polymorphisms and cetuximab response in metastatic colorectal cancer.
Study Patients Distribution 
of FCGR3A 
phenotypes 1
Treatment KRAS status of 
tumor
Results





Χ2 = 0.44 
p = 0.51
cetuximab Unknown Patients with any F 
phenotype showed 
favourable response 
(median PFS 3.7 vs.  
1.1 months p = 0.004).











No association found 
on progression free or 
overall survival.














type and KRAS 
mutant
VV phenotype 
associated with longer 
PFS. VV phenotype 6.9 
months vs. FV or VV 
phenotype 3.2 months 
in whole population. 
VV phenotype 5.5 
months vs. FV or VV 
phenotype 2.8 months 
in KRAS mutant 
patients
























seen in whole 
population 
and KRAS wild 
type patients.
No association found 
on response rate.
FF associated with a 
better response rate 
(56%) compared to FV 
(25%) and VV (8%)  
p = 0.05
Pander et al. 
2010 
270 FF: 119










type and KRAS 
mutant
V allele associated 
with decrease in PFS 
(VV and FV 8.2 vs 
12.8 months in FF and 
HR 1.56, p = 0.006) 
regardless of KRAS 
status





Χ2 = 1.89 
p = 0.17
Chemotherapy 








type and KRAS 
mutant
No association found 




Study Patients Distribution 
of FCGR3A 
phenotypes 1
Treatment KRAS status of 
tumor
Results












of KRAS wild 
type patients
Median OS was 9.8 
months in FF vs. 9.0 
in FV vs. 2.6 in VV 














prognosis for FF 
phenotypeMedian PFS 
VV, FV,FF; 18.2 vs. 17.3 




FV and VV: 
31







No association found, 
adjusted odds ratio for 
VV +FV was 3.8 (95% 
CI 0.5 -26)


















RR, OS or PFS









response rate or time to 
tumor progression





Χ2 = 1.19 
p = 0.27




type and KRAS 
mutant
None of the FCGR3A 
phenotype were 
associated with altered 
response





















between median PFS 
between VV vs. FF 
+FV, better DCR and 
median OS in KRAS 




Abbreviations: PFS, progression free survival; OS, overall survival; DCR, disease control rate; RR, response 
rate; CAPOX, capecitabine and oxaliplatin; FLOX, fluorouracil and oxaliplatin
1. If p < 0.05 not consistent with Hardy-Weinberg equilibrium.
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Material and Methods
Individual patient data acquisition
To study the association between survival times and FCGR3A polymorphism, a literature 
search was performed in June 2014 on PubMed, by using the keywords cetuximab, FCGR 
polymorphisms, KRAS and (metastatic) colorectal cancer. We used the following criteria to 
select publications: 
1. Treatment with cetuximab in mCRC;
2. Individual patient data regarding overall survival (OS) and progression free survival 
(PFS) or the individual patient data reconstruction using Kaplan Meier curves;
3. Availability of FCGR3A (rs396991) genotype;
4. Genotyping methods of eligible studies were reviewed to prevent inclusion of patients 
with an unreliable FCGR3A genotype. (Several methods do not discriminate between 
FCGR3A and FCGR3B, which may result in genotyping errors[26]); 
5. Availability of KRAS mutational status (KRAS codon 12, 13 and if possible 61) of the 
tumor (both KRAS wild type and mutant patient were included in this study).
This resulted in the inclusion of patients from three studies, the CAIRO2 [24], Rodriguez 
et al.[15] and the study of the European colorectal cancer consortium [30]. The FCGR3A 
polymorphism data from the European colorectal cancer consortium, was not published at time 
of analysis but the authors provided us with the data. Recently, the FCGR3A polymorphisms 
data from the European colorectal cancer consortium was published by Geva et al.[18]. All 
studies were approved by the local ethics committees and all included patients gave informed 
consent. Articles were excluded due to unknown KRAS status[13,31]. KRAS wild type patients 
only[19,21], genotyping method[16,20,22,23], missing survival data[14] and inability to provide 
the data[17].
Study 1: cohort CAIRO2 study
Data from 193 patients were available from the CAIRO2 study, which started in the pre-
KRAS era. These patients with mCRC were treated with firstline capecitabine, oxaliplatin and 
bevacizumab (CAPOX-B) or the same regimen plus cetuximab. Cetuximab was administered 
intravenously at a dose of 400 mg/m2 on the first day, followed by 250 mg/m2 weekly thereafter. 
Dose reductions were carried out according to the study protocol. The duration of a treatment 
cycle was three weeks. Treatment was continued until disease progression, death or unacceptable 
toxicity, whichever occurred first.
Study 2: cohort Rodriguez et al.
Data were available from 99 patients. Patients with mCRC were treated with cetuximab 
administered on an every-second week schedule at a dose of 500 mg/m2 combined with standard 




Study 3: cohort European colorectal cancer consortium
From the European colorectal cancer consortium data were available from 1009 patients. Patients 
with mCRC were treated with irinotecan or oxaliplatin based chemotherapy and cetuximab or 
cetuximab monotherapy.
KRAS tumor status and FCGR3A rs396991 polymorphism
In all three studies, genotyping of the FCGR3A was performed on a validated realtime PCR 
system with a predesigned assay for FCGR3A rs396991 (C__25815666_10). Details about the 
used methods are described elsewhere [15,30,32]. 
Outcome measures
The association between FCGR3A rs396991 genotype and the primary endpoint PFS and the 
secondary endpoint OS were investigated. PFS was calculated as time from randomisation to 
the first documented progression, death or loss to follow up, whichever occurred first. OS was 
estimated from time since randomisation to death or loss to follow up.
Statistical analysis 
Meta-analysis based on the survival outcomes coming from the three studies described above 
was performed, for two studies individual patient data were available while for the third study 
individual patient data were reconstructed from the estimated PFS and OS. Reconstruction 
of the relevant data is discussed by Fiocco et al. [33,34]. Further details on data analysis are 
described in appendix 1. A multivariate mixed effects Cox proportional hazard model with study 
as random effects was employed to investigate the effects of FCGR3A, KRAS mutation status 
and the interaction between FCGR3A and KRAS on the primary endpoint PFS and secondary 
endpoint OS. 
Results
Individual patient data meta-analysis
A total of 1,301 patients were included in the analysis. In table 2 an overview of the incidence 
of FCGR3A polymorphism and KRAS tumor status is shown. For all three studies, the reported 
FCGR3A genotypes were in Hardy-Weinberg equilibrium. To study the effect of FCGR3A 
polymorphisms, we used a dominant genetic model (FF vs non FF). Table 3 shows an overview 
of the median PFS and OS for the three different studies for FCGR3A FF and non FF. 
Progression free survival
The hazard ratio (HR) for FCGR3A non FF, adjusted for KRAS and the interaction between 
FCGR3A and KRAS was equal to 1.07 (95% confidence interval 0.89 – 1.29, p = 0.45). The 
estimated pooled Kaplan Meier curves, for patients with KRAS mutant and wild type tumors 
and FCGR3A FF and non FF status, are shown in Figure 1. A small, non-significant effect is 
seen between FCGR3A FF and non FF, stratified for KRAS status of the tumor. For patients 
with KRAS wild type tumors, median PFS was equal to 14.0 (95% CI interval 12.5 – 15.9) and 
15.2 (95% CI interval 14.0 – 17.1) months for FCGR3A FF and non FF respectively. For patients 
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with a KRAS mutant tumor PFS was 10.6 (95% CI interval 9.0 – 13.1) and 9.2 (95% CI interval 
8.0 – 11.3) months for FCGR3A FF and non FF, respectively. 
Table 2: distribution of FCGR3A polymorphisms
Polymorphism or 
mutation



































HWE p-value1 0.45 0.32 0.15 0.06
 
Abbreviation: HWE: Hardy-Weinberg Equilibrium. 
1. If p < 0.05 not consistent with Hardy-Weinberg Equilibrium.
Table 3: Median PFS and OS for cetuximab treated KRAS wild type and mutant patients
Study Treatment FCGR3A Median PFS Median OS
1:
CAIRO2



















Irinotecan/ oxaliplatin based 
chemotherapy +cetuximab 








The HR for FCGR3A non FF, adjusted for KRAS and the interaction between FCGR3A and 
KRAS was 0.91 (95% confidence interval 0.77 – 1.07). In figure 2 the pooled Kaplan Meier curves 
for patients with KRAS mutant and wild type tumors, and FCGR3A FF and non-FF status are 
depicted. A difference between patients with a KRAS wild type and KRAS mutant tumor was 
observed in the plots, although this difference is not significant. For patients with KRAS wild 
type tumor, median OS was equal to 37.3 (95% CI interval 33.1 – 45.3) and 46.3 (95% CI interval 
39.0 – 54.0) months for FCGR3A FF and non FF respectively. For patients with KRAS mutant 
tumor median OS was equal to 27.7 (95% CI interval 22.6-35.2) and 21.5 (18.9-26.4) months for 
FCGR3A FF and non FF respectively.
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Figure 1: Estimated Kaplan Meier curves for progression free survival in patients treated with cetuximab, 
stratified by KRAS tumor status and FCGR3A status. 
Abbreviations: PFS: progression free survival, FF_WT: FCGR3A FF and KRAS wild type; Not FF_WT, 
FCGR3A not FF and KRAS wild type; FF_MT, FCGR3A FF and KRAS mutant; Not FF_MT, FCGR3A not 
FF and KRAS mutant
Figure 2: Estimated Kaplan Meier curves for overall survival in patients treated with cetuximab, stratified 
by KRAS tumor status and FCGR3A status.
Abbreviations: FF_WT: FCGR3A FF and KRAS wild type; Not FF_WT, FCGR3A not FF and KRAS wild 
type; FF_MT, FCGR3A FF and KRAS mutant; Not FF_MT, FCGR3A not FF and KRAS mutant
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Discussion
The meta-analysis performed in this study indicates that the FCGR3A (rs396991) polymorphism 
is not associated with progression free or overall survival in patients with metastatic colorectal 
cancer treated with cetuximab in patients with either a KRAS mutant or KRAS wild type tumor. 
In our meta-analysis we did not find any advantage for the FF genotype in terms of clinical 
efficacy. 
Both KRAS wild type and mutant metastatic colorectal cancer patients were included in the 
analysis, since the interesting results seen in the preclinical[29] and CAIRO 2[24] study. This 
meta-analysis however shows that there is no difference between the KRAS wild type and mutant 
populations. 
Nowadays cetuximab is used in RAS wild type patients only. In the three included studies 
only the KRAS status of the tumor was known. Unfortunately, we were not able to extend 
our research to the effect of FCGR3A in the RAS mutant colorectal cancer patient due to the 
retrospective design of the studies included in this meta-analysis. Most probably the including 
RAS mutant colorectal patients in the analysis would not have altered the outcome of this study
Differences between studies due to a specific design and methodology, clinical procedures, 
different lines of chemotherapy and patients’ characteristics can contribute to variability 
in treatment effect among studies. Heterogeneous studies are a common problem in meta-
analysis[36]; to take into account the inter-trial heterogeneity caused by different treatments and 
lines of therapy used in these studies, we performed a meta-analysis by including studies as 
random effects, allowing for differences in the treatment effect and different regimens used from 
study to study and providing a more efficient estimate of the average treatment effect[37]. 
The inconsistent finding in studies concerning FCGR3A polymorphism and cetuximab 
efficacy shows the importance of genotyping methods, appropriate sample size and proper use 
of statistical methodology. We pooled data concerning 1,301 patients to improve the statistical 
power to detect the presence of a treatment effects on survival. Instead of reporting the classical 
forest plot based on hazard ratio for each individual study, we performed a meta-analysis based 
on individual patient data, which gave a better estimation of the potential benefit of FCGR3A FF 
status by using the individual patient data. An individual patient data meta-analysis approach of 
time to event outcomes, although usually more demanding, allows a deeper investigation. 
Advanced and metastasizing CRC and prior lines of chemotherapy may be linked to 
decreased immune responses and impaired natural killer cell dysfunction and consequently 
failure of cetuximab treatment[38-40]. This may result in a more limited role of ADCC in 
cetuximab treated patients with advanced disease. Noteworthy, patients from CAIRO2 received 
concomitant chemotherapy and in this study, a difference in median PFS between FCGR3A FF 
and non FF was observed. Nonetheless, no difference was seen for FCGR3A on median OS.
In this meta-analysis we have studied the FCGR3A polymorphism rs396991 but ADCC is 
a complex biological process and a more in-depth analysis of alternative crucial steps in the 
immunological pathway may be of influence. Consideration of other FCGRs, MHC expression, 
IFN-gamma pathway components and antigen processing machinery genes might provide a 
broader insight into the role of immunity in cetuximab efficacy.
In conclusion, our results do not support a predictive role for the FCGR3A polymorphism 
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Appendix 1: data reconstruction
Starting point for the meta-analysis are the estimated survival curve reported for each study and 
the minimum and the maximum follow up (minFUP and maxFUP) of patients. These quantities may 
be given directly but most often they will need to be estimated from the manuscript by looking 
at dates of accrual (if given) and from the date of submission, or perhaps publication of the 
manuscript. A model for the censoring mechanism based on the minimum and the maximum 
follow up is assumed here for computing the number at risk and person years for each time. Let 
C(t) be the function that models the censoring mechanism. Based on the available information 
we choose the function C(t) as follows
This function expresses the proportion of patients at time t that have at least t time units of 
follow-up. Given the number of eligible patients (n), the effective number at risk, the number of 
revisions at time j and the number of censored are estimated, respectively, as
This assumes that the censored observations are distributed uniformly over the interval. Under 
the same assumption, from the number of patients at risk rj , we can determine the number of 
person-years over interval Ij , as rj = ∆j (rj – cj / 2), where ∆j = tj – tj-1 the length of Ij . Following 
the methodology described the data for each study involved in the meta-analysis have been 
reconstructed. A model with study as random effects has been fitted to the reconstructed data, 
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Pharmacokinetics of panitumumab 






Panitumumab is used for the treatment for metastatic RAS wild type colorectal cancer 
(mCRC). It is likely that many of these patients will present with liver metastases and some 
with liver dysfunction. The pharmacokinetics in patients with hepatic impairment has not been 
investigated, and dosage adjustments are undetermined. Here, we present a case of a patient with 
progressive mCRC and liver dysfunction.
Method
A heavily pretreated KRAS wild type mCRC patient with liver disease Child-Pugh class B was 
treated with 2-weekly intravenous panitumumab (6 mg/kg). The patient received 2 doses of 490 
mg i.v. panitumumab after which progressive disease was documented. Toxicities were graded 
using CTCAEv4.0. Serum samples were collected, and panitumumab concentrations were 
determined using a validated immunoassay. Pharmacokinetic parameters after the first dose, 
including dose-normalized AUC from time zero–day 14, clearance (CL), and elimination half-
life (T1/2), were estimated via trapezoidal noncompartmental methods. Data were compared to 
historical data from a population with adequate liver function, as reported by Stephenson (Clin 
Colorectal Cancer, 8:29–37, 2009). Values within the range of the mean ± 1 standard deviation 
(SD) were considered not deviant.
Results
Calculated AUC after the first dose of 6 mg/kg panitumumab in this patient with hepatic 
dysfunction was 877 μg day/mL (Stephenson’s cohort 1: 744 ± 195 μg day/mL). Estimated T1/2 
was 3.58 days (5.28 ± 1.90 days), and CL was 6.9 mL/day/kg (8.21 ± 3.79 mL/day/kg). Estimated 
PK parameters during the first cycle were inside reported mean ± 1 SD of historical controls 
without liver dysfunction. No toxicity was reported during treatment; particularly, no diarrhea 
and skin toxicity were noticed.
Conclusion
The pharmacokinetics of panitumumab in this patient suffering from metastatic colorectal 
cancer with liver dysfunction Child-Pugh class B was similar compared to patients with adequate 
liver function. Moreover, no substantial toxicity was detected. The here-presented data may help 
clinical decision making in real-life practice. Two-weekly panitumumab monotherapy seems to 
be safely applicable in patients with KRAS wild type mCRC and hepatic dysfunction, without the 
need for any dose adjustments.
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Pharmacokinetics of panitumumab in a patient with hepatic dysfunction
Introduction
Panitumumab is a fully human IgG2 monoclonal antibody targeting the EGFR receptor. 
Panitumumab is approved for the treatment for patients with wild type RAS metastatic colorectal 
cancer (mCRC). In the first line, panitumumab is indicated in combination with FOLFOX and in 
the second line with FOLFIRI for patients who have received first-line fluoropyrimidine-based 
chemotherapy (excluding irinotecan). Panitumumab as monotherapy is indicated after failure of 
fluoropyrimidine, oxaliplatin, and irinotecan containing regimens. 
As panitumumab is used in treatment for metastatic colorectal cancer, it is likely that 
many of these patients will present with liver metastases and hence some even with significant 
liver dysfunction. In the pharmacokinetic studies of Weiner et al., Rowinsky et al., Ma et al., 
and Stephenson et al. [1–5], the pharmacokinetics of panitumumab have been described 
comprehensively. However, panitumumab has not been studied in patients with hepatic 
dysfunction.
Knowledge on the dosing in liver impaired patient is highly relevant; particularly, since in the 
panitumumab productinformation guidelines, advices for dosing in hepatic failure are lacking 
[6]. The clearance of panitumumab occurs via two pathways. Panitumumab can be cleared via 
an EGFR sink, which results in saturation of the receptor with panitumumab and consequent 
clearance. Secondly, the clearance via the reticuloendothelial system is also present in the liver. 
The capacity of this system is extensive, due to large numbers of receptors in the body. So dose 
adjustments may not be necessary in case of liver dysfunction. 
Here, we report on the pharmacokinetics of panitumumab in a single patient with hepatic 
dysfunction treated with single agent 6 mg/kg panitumumab intravenously administered. The 
objective of this case study is to describe and discuss the effects of hepatic impairment on the 
pharmacokinetics of panitumumab and to compare the pharmacokinetic data with data from 
patients without impaired hepatic function.
Subject and methods
Case presentation
In December 2005, a 60-year-old Caucasian male was diagnosed with a T3N + M0 colon 
carcinoma. The tumor was completely resected, and the patient was treated adjuvantly with eight 
cycles of capecitabine combined with oxaliplatin (CAPOX). In March 2009, the patient presented 
with metastatic disease and received a UFT/leucovorin plus bevacizumab regimen, followed by 
three-weekly irinotecan from January until April 2010. 
In August 2010, the patient presented with progressive disease and liver dysfunction, Child-
Pugh class B, with bilirubine, gamma GT, ALAT, and ASAT all elevated (Table 1). Treatment 
with two-weekly 6 mg/kg panitumumab was suggested despite the present hepatic dysfunction. 
Panitumumab is not contra-indicated in patients with hepatic dysfunction; however, it has not 
been studied in patients with hepatic impairment [6]. Since there is no clinical data supporting 
dose adjustments in patients with hepatic impairment, it was decided to start at the regular dose 
and to measure the panitumumab serum levels in this patient. In total, the patient received two 
cycles of panitumumab, after which disease progression was documented.
122
Chapter 8




















Sodium (mmol/) 136–144 137 130 125 130 140 140
Potassium (mmol/L) 3.6–4.8 4.4 4.2 4.2 3.3 3 4.6
Ureum (mmol/L) 2.5–7.5 9.3 10.7 14.4 10.2 3 14.4
Creatinine 62–106 112 90 96 98 63 127
eGFR (mL/min) >60 58 >60 >60 >60 >60 50
Albumin 34–48 44 43 34 18
Bilirubin total (μmol/L) 0–17 148 136 63 40 31 165
Bilirubin conjugated 
(μmol/L)
0–5 109 95 43 25 19 125
Alkaline phosphatase 
(U/L)
40–120 232 184 133 213 293 635
Gamma GT (U/L) 5–55 230 175 164 408 498 348
ASAT (U/L) 5–35 89 91 114 69 62 207




To study the effects of panitumumab in this patient with hepatic dysfunction, serum samples 
were collected to determine the serum drug concentrations. The patient, with a body weight of 
81 kilograms, received two cycles, 14 days separated (day 1 and day 15), of 490 mg panitumumab, 
according to the approved dosing instructions of 2-weekly 6 mg/kg body weight. Further dosing 
was stopped due to early disease progression.
In both instances, panitumumab was administered intravenously in 1 hour. Serum samples 
were collected at 0.5, 1, 2, 4, 8, 24 hour, 4 days, and 7 days after the first panitumumab infusion. 
In addition, just before the second infusion (day 15) and 30 minutes and 1 hour after the second 
infusion, blood samples were drawn [3].
The samples were allowed to clot for 30 minutes, followed by centrifuging at 3,000 rounds per 
minutes. The serum was transferred to a tube and stored at −80 °C until analysis. Panitumumab 
serum drug concentrations were performed by PPD (Richmond, VA, USA) using a validated 
immunoassay with electrochemiluminescence detection as follows. Microplate wells were 
coated with mouse panitumumab antibody to capture the panitumumab. Standards, quality 
controls, study samples, and blank were loaded into the wells after pretreating 1:100 with 1 × 
PBS containing 1 % BSA, 1 M NaCl, and 0.5 % Tween-20. The panitumumab in the standards, 
controls, and samples was captured in the wells, and unbound materials were removed by 
washing the cells. Horseradish peroxidase labeled rabbit panitumumab antibody was added to 
the wells for detection. After washing, tetramethylbenzidine peroxidase substrate was added to 
the wells. The produced colorimetric signal produced after the reaction was proportional to the 
amount of panitumumab. The color development was stopped by addition of 2 N sulfuric acid, 
and the optical density was measured at 450–650 nm.
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For an analytical run to be acceptable, a minimum of six acceptable calibration standard levels was 
required to generate an acceptable calibration curve, and a minimum of four out of six controls 
with at least one control at each level must meet the method acceptance criteria (difference ±20 
% and coefficient of variation ≤15 %). The nominal assay range was 400–20,000 ng/mL. If the 
sample was outside the upper limit, the sample was repeated at an increased dilution. If the 
sample was below the lower limit and the dilution factor was one, the sample was reported as 
below the quantification limit (<400 ng/mL).
Pharmacokinetic parameters
Pharmacokinetic parameters were estimated by trapezoidal noncompartmental methods using 
MW/PHARM 3.5 of Mediware (Groningen, The Netherlands) [7]. Pharmacokinetic parameters 
for panitumumab i.e., area under the serum concentration–time curve from time zero to 14 days 
(AUC0–14), maximum observed serum concentration (Cmax), and minimum observed serum 
concentration (Cmin)—were determined. Half-life (T½) and clearance (CL) were calculated.
For comparison, historical data from the Summary of Product Characteristics (SPC) [6] 
and cohort 1 of Stephenson et al. [4] were used. From this study, the dose-normalized (for the 
first dose of 6 milligram per kilogram) AUC, clearance, elimination half-life, minimum and 
maximum concentrations were used. In case the value was within the reported serum level ±1 
standard deviation, the found value was considered not to be clinically relevant or clinically 
different.
Toxicity
Information on toxicities was scheduled to be collected at baseline, just before each course, 
at the day of infusion and 7 days after infusion. Information on toxicities was also scheduled 
to be collected during each unplanned hospital visit or contact. Toxicities were graded using 
CTCAEv4.0.
Results
The Cmax measured in this patient was 176 μg/mL after the first infusion and 164 μg/mL after the 
second infusion. The Cmin (10.5 μg/mL) was determined just before the second administration 
of panitumumab. The reported serum concentrations of panitumumab have been used to 
calculate the AUC0–14 (μg day/mL), half-life (days), and clearance (mL/day/kg) (Table 2).
In Table 2, the pharmacokinetic parameters of panitumumab in this patient with Child-
Pugh class B liver dysfunction are reported. In this table, the historical pharmacokinetic data 
of panitumumab in patients with normal liver function are shown as well [4, 6]. In Figure 1, the 
plasma concentration versus time curves are shown. In summary, in our patient, the calculated 
AUC was 877 μg day/mL.
In Stephenson’s cohort 1 [4], after the first dose of 6 mg/kg, a mean AUC of 744 ± 195 μg day/
mL was calculated. The half-life calculated in our single patient was 3.58 days with a calculated 
clearance of 6.9 mL/day/kg. The study of Stephenson reported a half-life of 5.28 ± 1.90 days and 
a clearance of 8.21 ± 3.79 mL/day/kg. All these parameters following the first administration 
of panitumumab reported in our patient with severe liver dysfunction are within the range 
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of one standard deviation around the mean of the data reported for cohort 1 in the study of 
Stephenson [4]. Likewise, the maximum and minimum concentration, elimination half-life, and 
clearance were comparable (Figure 1 and Table 2). A difference between the data from the SPC 
and parameters after the third dose was noted; however, it should be noted that these parameters 
were not determined following single dose but after multiple dosing, in the steady state phase.
Table 2: Historical comparison of pharmacokinetic parameters of panitumumab of the single 
patient with severe liver dysfunction with patients with adequate liver function










Cohort 1 first dose 6 mg/kg 
(2-weekly) Stephenson
152 (29.2) 18.1 (8.6) 744 (195) 5.28 (1.90) 8.21 (3.79)
Cohort 1 third dose 6 mg/kg 
(2-weekly) Stephenson
232 (71.2) 46.6 (16.9) 1,310 (375) 9.08 (3.61) 4.96 (1.49)
SPC 6 mg/kg (2-weekly) 213 (59) 39 (14) 1,306 (374) 7.5 4.9
Case first dose 179 10.5 877 3.58 6.9
Case second dose 164 n/a n/a n/a n/a
Figure 1: Time curve of serum panitumumab serum concentrations following 1 h infusion of 690 mg  
(6 mg/kg) panitumumab in a metastasized colon cancer patient with Child-Pugh B liver dysfunction
 
In our patient with Child-Pugh class B liver dysfunction, no toxicity was recorded after the first 
two doses of panitumumab; specifically, no diarrhea and no skin toxicity were seen.
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Discussion
No advice on the necessity of adjusting the dose of panitumumab, a fully human antibody 
targeting the EGFR that is dosed two-weekly, in special populations, such as patients with 
hepatic dysfunction, is available. Also, the safety and pharmacokinetics have not been studied 
specifically in patients with liver impairment. Like other EGFR targeting agents, panitumumab 
only has been tested in clinical trials in metastatic colorectal cancer in selected populations with 
adequate laboratory tests and good performance characteristics. In real-life practice, however, 
many patients do not match these criteria and may present for example with severe liver 
dysfunction. There is a clear need for studies in different populations to guide the clinician in 
real-life practice[8].
The here-reported results of our pharmacokinetic study in a single, heavily pre-treated patient 
suffering from metastasized colorectal cancer treated with 6 mg/kg 2-weekly monotherapy 
panitumumab do not indicate the necessity of any dose adjustments in patients with liver 
dysfunction and appear to be tolerable and safe. Pharmacokinetic parameters reported are 
within the range of one single standard deviation of previously reported data in patients with 
adequate liver functions. In addition, no substantial toxicity was noticed. However, larger studies 
of panitumumab in liver impaired patients are needed before firm conclusions can be drawn, 
and a more solid advice on the necessity of dose adjustments in patients with various degrees of 
hepatic dysfunction can be given. 
The side-effect profile of cetuximab in a liver impaired patient has been presented recently by 
Moosman et al. [9]. In that particular case report, Moosman and colleagues report on a 57-year-
old metastasized colorectal cancer patient with severe liver dysfunction that was successfully 
treated with cetuximab, a weekly administered chimeric monoclonal antibody targeting the 
EGFR as well. Based on their observation, it was concluded by the authors that cetuximab is 
an effective treatment in patients who cannot be treated with cytotoxic agents due to hepatic 
dysfunction. However, no pharmacokinetic data are presented. The here reported data on 
panitumumab add to their conclusion. However, it should be noted that there are important 
differences between the EGFR antibodies cetuximab and panitumumab. For example, cetuximab 
is a chimeric antibody, whereas panitumumab is a fully human antibody. Next, cetuximab is 
an IgG1 antibody, whereas panitumumab is an IgG2 antibody. As a consequence, the serum 
clearance, Fc domain interactions, and potential initiation of ADCC differ between both 
antibodies. Therefore, it is not possible to directly extrapolate the pharmacokinetic profiles of 
one of these antibodies to the other [10].
Successful treatment for solid tumors relies on the ability of EGFR inhibitors to penetrate 
into the tumor tissue. Clearance of both panitumumab and cetuximab occurs by the EGFR 
sink and the reticuloendothelial system. Their clearance may also partly depend on the EGFR-
positive tumor burden and antigen density in the tumor, i.e., a high tumor burden and/or a 
high density of EGFR may lead to subsequent higher clearance of panitumumab. In our patient, 
unfortunately, the tumor burden and the antigen density in the tumor were not known. The 
impact of EGFR binding sites in the liver on serum clearance of EGFR antibodies remains to be 
fully clarified. A study of Schechter et al. with 99MTC-cetuximab, however, indicated that the 
liver may not have any EGFR binding sites, but simply extracts EGFR antibodies, which are not 
cleared elsewhere in the body [11]. This aforementioned extraction by the liver and the impact of 
liver dysfunction on total EGFR antibody clearance needs further clarification.
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In conclusion, the pharmacokinetics of panitumumab in our single patient suffering from 
metastatic colorectal cancer with liver dysfunction Child-Pugh class B do not seem to be altered 
compared with patients with adequate liver function. Moreover, no substantial toxicity was 
noticed. Based on these data, panitumumab can be considered safe for treatment in patients with 
hepatic dysfunction without any dose adjustment. However, more studies seem warranted before 
firm conclusions can be drawn to guide clinical decision in daily practice.
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In the literature data on the effect of renal impairment on the pharmacokinetics of anticancer 
drugs are scarce. Here, we report a 68 year old metastatic osteosarcoma patient with impaired 
renal function due to prior chemotherapy, who was treated on compassionate use basis with 400 
mg/m2 cetuximab. Pharmacokinetic parameters after the first dose, including dose normalised 
AUC from time zero to day 7 (AUC0-7), clearance (Cl), elimination half-life (t1/2) were estimated 
using trapezoidal non compartmental methods and compared to pharmacokinetic data from a 
study population with normal kidney function. These results showed that the pharmacokinetics 
of cetuximab in this patient with renal failure was similar to that with adequate renal function 




Pharmacokinetics of cetuximab in a patient with renal dysfunction
Introduction
Cetuximab is a monoclonal antibody, targeting epidermal growth factor receptor (EGFR) and 
registered for the treatment of colorectal and head and neck cancer. During its development, the 
drug has been investigated in patients with adequate renal and hepatic function only and a dose 
of 250 mg/m2 every week, after an initial loading dose of 400 mg/m2, is defined in the summary 
of product characteristics. 
No specific dose recommendations are given for patients with renal impairment (http://
packageinserts.bms.com/pi/pi_erbitux.pdf). The elimination of antibodies occurs via both 
nonspecific intracellular catabolism, following fluid-phase endocytosis, and receptor-mediated 
elimination after binding to their target antigen. Part of cetuximab clearance is therefore 
explained by binding to EGFR. Clearance of the EGFR antibody cetuximab seems independent 
of the liver and kidney function[1]. In addition, there are four case reports[2-5] of haemodialysis 
patients who could safely be treated with standard doses of cetuximab. The aim of this study was 
to determine the pharmacokinetics of the conventional dose cetuximab in patients with impaired 
renal function and to compare it to published data obtained in populations of cetuximab treated 
patients with normal renal function. 
Method
Case presentation
We treated a 68 year old metastatic osteosarcoma patient with impaired renal function due to 
prior chemotherapy on compassionate use basis with 400 mg/m2 cetuximab. The serum creatinine 
of this patient was 128 µmol/L. The glomerular filtration rate (GFR) was 35 mL/min/173 m2, 
calculated with the MDRD formula (0.742 * 175 * Serum creatinine-1.154 * Age-0.203). The GFR, 
calculated with the Cockcroft-Gault formula was 41 mL/min (0.85 * (140 - Age) * Weight) / 
(72 * Serum creatinine). This treatment was based on preclinical data on cetuximab activity 
in osteosarcoma[6] and the lack of other treatment options. The medical ethical committee 
approved the treatment and the pharmacokinetic analysis and the patient gave informed 
consent. The starting dose was 740 mg, preceded by the recommended 2 mg of the antihistamine 
clemastine, to avoid an allergic reaction to cetuximab. 
Sample collection
Cetuximab was infused over two hours. Serum samples were collected 2, 3.5, 4.5, 44 and 168 
hours after the end of the infusion in line with a previous pharmacokinetic study[7]. Cetuximab 
serum concentrations were measured using a validated immunoassay[8]. Limit of detection was 
0.012 µg/mL and lower limit of quantitation (LLOQ) was 0.75 µg/mL. 
Pharmacokinetic parameters
Pharmacokinetic parameters after the first dose, including dose normalised AUC from time zero 
to day 7 (AUC0-7), clearance (Cl), elimination half-life (t1/2) were estimated by trapezoidal non 
compartmental methods using MW/PHARM 3.5 (Mediware, Groningen, The Netherlands). 
Results were compared to historical data on cetuximab in patients with normal renal function as 




The maximum concentration (Cmax), measured at the end of the 2 hour infusion, in this patient 
was 297 µg/mL, the minimum concentration (Cmin or through level) was 34.4 µg/mL. The 
reported serum concentration profile, shown in figure 1, was used to calculate the AUC, Cl and t ½. 
In table 1, an overview of the pharmacokinetics of cetuximab in study populations with normal 
renal function and in this case are shown (2;9;10). In this table the pharmacokinetics after a 
single dose of 400 mg/m2 are depicted, and are used for comparison.
Figure 1: Time curve of cetuximab serum concentration following two hour infusion of 740 mg cetuximab 
in a patient with a glomerular filtration rate of approximately 35 mL per minute.
In this patient the calculated AUC after the first dose was 20,280 µg*day/mL. The half-life after a 
single dose of cetuximab was 53.2 hours with a calculated clearance of 32.6 mL/h. The Cmax was 
approximately 30% higher compared to the Cmax in the studies of Tan et al. and Fracasso et al. 
(9;10)The other parameters Cl, AUC, T1/2 and V are comparable as reported in those 2 studies. 
The half-life of cetuximab in our patient is 30% shorter than that calculated in the studies. 
During the first course of cetuximab, the patient experienced adverse effects: reversible 
grade 2 hallucinations and fatigue. After careful considerations these symptoms were deemed 
to be most likely caused by the 2 mg clemastine. Due to these side effects the patient refused 
further treatment with cetuximab. Little is known about the pharmacokinetics of clemastine, 
nonetheless, normally no dose reductions are advised in patient with renal impairment.
Cetuximab-related side effects such as skin toxicity and diarrhoea did not occur in this 
patient during the first course.
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Table 1: Pharmacokinetic parameters of the case and historical data from three studies.
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n/a n/a n/a 25 285 7.56
Abbreviation: n/a = not applicable
Discussion
This case report shows that the pharmacokinetics of cetuximab in a patient with renal failure is 
similar to that with adequate renal function. Different studies investigated the pharmacokinetics 
of cetuximab in population with adequate renal function. For the comparison, studies with 
single doses were used. Most of the studies reported cetuximab pharmacokinetic parameters at 
steady state after a loading dose of 400 mg/m2 followed by weekly doses of 250 mg/m2. Using a 
loading dose, steady state is usually reached within three weeks. Since this patient discontinued 
therapy after one single infusion, we can only compare this single dose to similar administrations 
available in the literature.
Our study shows some difference between the estimated parameters in our patient and patients 
with normal renal function. Due to inter patient variability, nonetheless, overall the kinetic profile 
is in line with the population with adequate renal function. Cetuximab pharmacokinetics are not 
studied in patients with impaired renal function, four case reports[2-5] studied the kinetics of 
cetuximab in patients undergoing haemodialysis. These four case studies showed that cetuximab 
in a patient with haemodialysis may be safely used. The estimated pharmacokinetic parameters 
were comparable to cetuximab patients with normal kidney function. Our study shows, for the 
first time, that pharmacokinetic parameters were also not altered in a patient with decreased 
renal function without haemodialysis.
At 3.5 hours, a lower cetuximab concentration was measured compared to the concentration 
measured at 4.5 hours. This appears to be noise from a single patient because these time points 
were very close to each other, these concentrations were measured shortly after infusion of 
cetuximab and the concentration of cetuximab decreases only slowly at this interval. Many drugs 
that enter the market are studied in a patient population with normal renal function and no 
dose recommendations are made for patients with impaired organ function and formal organ 
impairment studies are lacking. This is also the case for cetuximab. Other than from common 
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sense and four case reports in haemodialysis patients there was no information available to guide 
our decision on how to use cetuximab in this patient. As renal impairment is a common problem 
in head and neck cancer patients due to prior cisplatin chemotherapy and in colorectal cancer 
patients due to the high incidence of the disease our finding of no clinically relevant alteration of 
cetuximab pharmacokinetics in our patient with impaired renal function has clinical importance 
for dose guidance in future patients.
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The epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab are both 
registered for the treatment of RAS wild type metastatic colorectal cancer (CRC). About 40% of 
the patients have a tumor with a mutation in the KRAS gene. In patients with a KRAS mutant 
tumor KRAS is permanently activated which lead to constant cell signaling and proliferation 
independent of the EGFR. Patients with a (K)RAS mutant tumor are considered not to benifit 
from anti-EGFR therapy. The use is limited to patients with KRAS wild type tumors and more 
recently in RAS wild type only[1,2]. After having become chemotherapy refractory, treatment 
options are limited for this substantial patient group [3]. This means there is an urgent need to 
optimize anti-EGFR therapy.
This thesis investigates several strategies to refine EGFR targeted monoclonal antibody 
therapy in CRC by:
- statins and their ability to phenoconvert KRAS mutant CRC;
- exploration of polymorphisms in the gene encoding FCGR3A and their association 
with cetuximab efficacy;
- Investigating the pharmacokinetics of cetuximab and panitumumab in patients with 
renal or hepatic dysfunction. 
Statins and their ability to phenoconvert KRAS mutant CRC
Statins are commonly used to reduce cholesterol levels in patients in order to reduce the 
risk for cardiovascular events. Statins inhibit HMG-CoA-reductase in the mevalonate 
pathway and subsequently the formation of cholesterol. Besides cholesterol the formation of 
farnesylpyrophophate (a C15-group) and geranylgeranylpyrophosphate (a C17-group) are also 
inhibited. These C15 and C17 groups are used to prenylate the KRAS protein. Prenylation is an 
essential step in the activation of the KRAS protein. After prenylation, KRAS becomes more 
lipophilic and associates with the plasma membrane. By preventing prenylation and plasma 
membrane association the over-activated KRAS protein may be inhibited. We theorised that the 
inhibitory effect of statins may normalise the KRAS mutant phenotype into a more KRAS wild 
type phenotype and render KRAS mutant colorectal cancers sensitive to EGFR antibodies. Thus, 
statins may inhibit the expression of the mutant KRAS phenotype by preventing prenylation (the 
addition of C15 or C17 groups) of the KRAS protein. 
Besides statins, other KRAS modulators, such as bisphosphonates, farnesyltransferase 
inhibitors or geranylgeranyltransferase inhibitors, also affect the mevalonate pathway. These 
KRAS modulators might augment the effect of EGFR antibodies in patients with KRAS 
mutations. In chapter 2, clinical studies with these KRAS modulators and their outcomes were 
reviewed. This review indicates that combinations of EGFR antibodies to target the EGFR with 
KRAS modulators may be effective in patients with KRAS mutant tumors. 
To understand the role of statins in CRC and to explore the potential of therapeutic 




cell lines was performed. A survival assay was used to study the effects of simvastatin and 
cetuximab on proliferation in colorectal cancer cell lines. In KRAS G13D mutated HCT116 
and LoVo cell lines a combination of simvastatin pre-treatment and cetuximab induced a small 
reduction in growth (chapter 3). This effect was not observed in the SW480 cell line harboring a 
codon 12 KRAS mutation. The observation that codon 13 KRAS mutated tumors are responsive 
to EGFR-antibody therapy is in line with other retrospective studies[4-6], which also showed a 
positive association on outcome for the KRAS codon 13 mutations. An in vitro study showed that 
codon 13 KRAS mutation may confer weaker transforming capacities on cancer cells, compared 
to other KRAS mutations[7]. Computational analysis revealed that the codon 13 mutated KRAS 
protein has a similar structure compared to the wild type protein [8]. Our studies revealed that 
all KRAS mutant cells showed a pronounced cytotoxic effect after simvastatin monotherapy. The 
effect of simvastatin on growth was not observed in the KRAS wild type A431 cell line. A possible 
explanation for the cytotoxic effect may be a strong dependence (‘’addiction”) of the mutant cells 
on permanently activated KRAS and its corresponding pathways. These pathways are possibly 
highly activated due to mutant KRAS. The observed effect of combination treatment with 
simvastatin and cetuximab was relatively small; therefore other pathways besides the RAS-RAF-
MAPK pathway may play important roles which are not affected by blocking the EGFR receptor.
As the in vitro studies (chapter 3) showed promising results, we decided to perform a 
retrospective analysis to evaluate the effect of statin use on outcome in KRAS mutant metastatic 
colorectal cancer patients (mCRC) treated with cetuximab. In the CAIRO2 study metastatic CRC 
patients were treated with capecitabine, oxaliplatin, bevacizumab with or without cetuximab. We 
retrospectively analysed the effect of statin use at time of diagnosis on progression free survival 
(PFS) in CRC patients with KRAS mutant tumors treated with cetuximab. Chapter 4 showed that 
the use of statins in patients with a KRAS mutant tumor was not associated with an improved PFS. 
To exclude a possible “generic” effect of statins on survival, patients with KRAS wild type 
tumors and patients in the study-arm without cetuximab were also included in the analysis. 
Additionally, the study design with an effect modifier helps to identify possible different effects 
of statins between patients with KRAS mutant and wild type tumors. 
Possible explanations for the lack of a modulating effect are that the cohort consisted of 
patients with metastatic disease and hence a relatively short PFS. The detection of a small to 
moderate effect on PFS may be difficult in this patient group. Another explanation for the absence 
of an effect was the concomitant use of bevacizumab in the CAIRO2 study. The combination 
of cetuximab and bevacizumab is not used nowadays, due to an unfavourable outcome. 
Hypertension, a common side effect of bevacizumab is also a prognostic factor for a better overall 
survival in CRC patients treated with bevacizumab [9]. A possible negative interaction between 
bevacizumab and cetuximab may have caused less hypertension in the cetuximab treated group, 
which contributed to the negative outcome of the CAIRO2 study. 
In two prospective studies we investigated the possibility of simvastatin to phenoconvert 
mutant KRAS in CRC patients treated with cetuximab or panitumumab. In the RASTAT C and 
P studies (chapter 5 and 6) metastatic CRC patients who failed on first- and second-line therapy, 
were treated with 80 mg of simvastatin daily and cetuximab (RASTAT C) or panitumumab 
(RASTAT P). Both studies were terminated after a planned interim analysis of the Simon two 
stage design, because similar survival as seen in KRAS wild type patients was not observed. 
In a similar study, Lee et al.[10] tested the addition of 80 mg of simvastatin to cetuximab and 
irinotecan. The disease controle rate in this study was 65.4%. Their original report indeed showed 
a low response rate (1 out of 52 patients had a partial remission), however PFS was 7.6 months, 
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which is even higher than historical results of third-line cetuximab plus irinotecan in KRAS wild 
type CRC patients. However, in a recent erratum Lee et al[30] reported corrected measurements 
of PFS in their population. Corrected mean PFS was 3.7 months (range 2.1-5.3), significantly 
lower than previous reports of cetuximab plus irinotecan as third-line therapy in KRAS wild type 
[10]. In summary, both our study as well as the study by Lee et al. shows that simvastatin does not 
render sensitivity to EGFR inhibitor therapy.
Polymorphisms FCGR3A gene and their association  
with cetuximab efficacy 
An important mechanism of cetuximab induced cell-killing is antibody-dependent cellular 
cytotoxicity (ADCC). Fc gamma receptors (FCGR) on effector cells, for example macrophages 
and natural killer cells, bind to the Fc fragment of the cetuximab molecule and this causes lysis of 
the cancer cell. The germline polymorphism (rs396991) in the Fc gamma receptor 3A (FCG3A) 
c.818A>C results in a change of phenylalanine to valine at codon 158. [11]. Previous results from 
studies investigating the association between FCGR3A polymorphisms and cetuximab efficacy 
are highly variable. A firm conclusion or direction of the effect of FCGR3A polymorphisms on 
cetuximab efficacy cannot be drawn from these studies. These inconsistent findings in studies 
may have been caused by incorrect genotyping methods[12] or insufficient statistical power[13]. 
In some studies [14-16], the observed allele frequencies were not in Hardy-Weinberg equilibrium, 
possibly because genotyping errors may have occurred due to FCGR3B co-amplification. 
The meta-analysis (chapter 7) performed on individual patient data shows that the FCGR3A 
polymorphism is not associated with improved survival in cetuximab treated CRC patients and 
there is no significant difference between patients with KRAS wild type and mutant tumors. Lack 
of effect of the FCGR3A polymorphisms may be explained by the fact that most patients were 
also co-treated with classic chemotherapy or patients received previous lines of chemotherapy, 
which suppresses macrophages and natural killer cells[17]. Moreover, all included patients had 
metastatic CRC, which may lead to decreased immune responses and impaired natural killer cell 
dysfunction in end stage CRC[18] and consequently failure of cetuximab treatment. 
Pharmacokinetics of cetuximab and panitumumab  
in patients with renal or hepatic dysfunction
Both panitumumab and cetuximab are used in patients with metastatic CRC. Some of these 
patients will present with hepatic impairment, due to liver metastasis. In addition, head and 
neck cancer patients are heavily pre-treated with chemotherapy and radiotherapy and may have 
decreased renal function. Cetuximab is used in these head and neck cancer patients because they 
cannot be treated with cisplatin, due to renal impairment. 
Knowledge of dosing in these specials populations with impaired renal or hepatic function 
is highly relevant. The pharmacokinetics and safety of both cetuximab and panitumumab have 
not been studied in these populations. In two case reports, with panitumumab and cetuximab in 
cancer patients with liver and kidney dysfunction respectively, we showed that dose adjustments 
in patients with liver or kidney failure are not necessary and that treatment appears to be tolerable 




needed before firm conclusions can be drawn to guide clinical decision making in daily practice. 
Successful treatment of solid tumors relies on the ability of EGFR inhibitors to penetrate into the 
tumor tissue. Clearance of both panitumumab and cetuximab occurs by the EGFR sink and the 
reticuloendothelial system. Their clearance may also partly depend on the EGFR-positive tumor 
burden and antigen density in the tumor, i.e. a high tumor burden and/or a high density of EGFR 
may lead to subsequent higher clearance of EGFR antibodies. In our patients the tumor burden 
and the antigen density in the tumor were not known. The impact of EGFR binding sites in the 
liver on serum clearance of EGFR antibodies remains to be fully clarified. 
Future research prospectives
In this thesis, the possibility of statins to phenoconvert the KRAS mutant protein to a more 
wild type protein to overcome EGFR-monoclonal antibody resistance in CRC was studied. The 
apparently promising results from the preclinical study, however, were not translated to the 
clinic. Statin use in the CAIRO2 study was not associated with a better progression free survival 
in cetuximab treated metastatic CRC patients with a KRAS mutant tumor. In the RASTAT C 
en P studies, the combination of cetuximab or panitumumab with simvastatin did not lead to 
a survival comparable with KRAS wild type patient. In these three studies we were not able to 
show that statins can phenoconvert the mutant KRAS protein and render these tumors sensitive 
for cetuximab. In this thesis, the hypothesis that statins can phenoconvert the mutant KRAS to 
a more favourable phenotype was studied only in patients with advanced colorectal cancer and 
thus with a short life expectancy. Recent evidence suggest that other RAS mutations (in exons 3 
and 4 of KRAS and exons 2, 3 and 4 of a related gene, NRAS) may also be predictive of anti-EGFR 
resistance. These other RAS proteins also requires post-translational farnesylation to become 
active. In further studies all RAS mutant patients need to be included.
A “perfect world” study where the effect of statins and concomitant chemotherapy and EGFR 
antibodies is studied in recently diagnosed (RAS mutant) patients who did not receive a statin 
before CRC diagnosis would be of great value. Since these patients have a longer life expectancy, 
lower tumor burden and possibly a phenotype, which could be modified by statin use. 
Besides statins, farnesyl- and geranylgeranyltransferase inhibitors also have a crucial role 
in the mevalonate pathway and consequently the prenylation of (K)RAS. Inhibiting of (K)
RAS prenylation might require combined treatment with these inhibitors. Possibly because of 
preclinical toxicity geranylgeranyltransferase inhibitors did not proceed to clinical stages. A 
combination of statin and low doses farnesyl- and geranylgeranyltransferase inhibitors may be 
an effective treatment in CRC patients with a (K)RAS mutant tumor. 
In this thesis we studied the effect of the FCGR3A gene, which is involved in antibody dependent 
cellular toxicity (ADCC). Other effector mechanisms and accompanying polymorphisms, such 
as complement-dependant cytotoxicity, phagocytosis and apoptosis may play a crucial and still 
unknown role in efficacy. The enormous complexity of cancer makes it debatable whether a single 
mutation or germ-line polymorphism might have a noteworthy effect on the tumor sensitivity to 
targeted therapies. Innovative technologies, such as next-generation sequencing, kinase activity 
profiling of tumors, computational biology and genome-wide association studies, will be useful 
in achieving a better overview of involved pathways and in further optimizing and personalizing 
the use of anti-EGFR monoclonal antibodies. By sequencing tumor DNA, targeted treatment can 
be optimized for the specific characteristics of the tumor.
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Many drugs that enter the market are studied in a patient population with adequate organ 
functions only[19]. No dose recommendations are made for patients with impaired liver or 
kidney function and formal organ impairment studies are lacking. This is also true for cetuximab 
and panitumumab. Other than from common sense and some case reports in haemodialysis 
patients[20-23], liver failure (chapter 8) and kidney failure (chapter 9), there is no information 
available to guide our decision on how to use cetuximab or panitumumab in these populations. 
Larger studies, where the efficacy and safety of EGFR antibodies and chemotherapies is 
studied in patients with liver and kidney dysfunction, will be of great value. Liver and kidney 
dysfunction will become more common, since patients are getting older and more treatments 
become available, which will substantially increase in the incidence of these cases. Development 
of new drugs should include studies in organ failure patients that reflect clinical dilemmas often 
encountered in routine patient care. Mandatory additional research with FDA or EMA approval 
would ensure this process on a timely basis.
Conclusions
The goal of this thesis was to refine EGFR monoclonal antibody treatment in CRC by four 
different strategies. The first strategy, focused on statins and their ability to phenoconvert KRAS 
mutant CRC Statin use in metastatic CRC patients with KRAS mutant tumors, did not affect 
progression free or overall survival. The second strategy explored polymorphisms in the gene 
encoding FCGR3A and their association with cetuximab efficacy. Neither of the FCGR3A 
polymorphisms showed a significant association with improved PFS. Although some studies 
reported that the effect of the FCGR3A polymorphisms on cetuximab efficacy is independent 
of KRAS. The meta-analysis showed that there is no significant difference between patients with 
KRAS wild type or mutant tumors. In conclusion, the result from these two strategies shows 
that the options for CRC patients with a KRAS mutation after failing first line chemotherapy 
and bevacizumab still remain poor. The outcomes from these strategies demonstrate that the 
involved pathways are very complex and urgently need further exploration.
The final strategy to optimize anti-EGFR therapy focused on the pharmacokinetics of 
cetuximab and panitumumab in patients with renal or hepatic dysfunction. The described 
case reports help clinical decision making in real-life practice. Cetuximab and panitumumab 
monotherapy seems to be safely applicable in patients with KRAS wild type metastatic CRC and 
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The use of the epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab 
is limited to colorectal cancer (CRC) patients with KRAS wild type tumors and more recently in 
RAS wild type only. After having become chemotherapy refractory, treatment options are limited 
for this substantial patient group. This means that there is an urgent need to optimize anti-EGFR 
therapy. The work presented in this thesis aimed at optimising EGFR targeted monoclonal 
antibody therapy in metastatic CRC. 
This thesis investigates several strategies to refine EGFR targeted monoclonal antibody 
therapy in CRC by:
- statins and their ability to phenoconvert KRAS mutant CRC; 
- exploration of polymorphisms in the gene encoding FCGR3A and their association 
with cetuximab efficacy; 
- and investigating the pharmacokinetics of cetuximab and panitumumab in patients 
with renal or hepatic dysfunction.
In patients with KRAS mutant tumors, the KRAS protein is highly active and these patients’ 
tumors do not respond to anti-EGFR therapy. Before the KRAS protein exerts its important 
function in the cell signaling cascade, prenylation of the KRAS protein is required. Prenylation 
is the addition of C15 and C17 fatty acid chains to the KRAS protein. Prenylated KRAS is more 
lipophilic and can easily associate with the membrane. Membrane association of KRAS is crucial 
for its function in the RAS-RAF-MAPK signaling pathway. Statins and other KRAS modulators, 
such as bisphosphonates, farnesyltransferase inhibitors or geranylgeranyltransferase inhibitors 
affect the prenylation of the KRAS protein. Inhibition of the prenylation may lead to a more wild 
type KRAS phenotype. The modification of the KRAS mutant phenotype to a more KRAS wild 
type phenotype may augment the effect of EGFR antibodies in patients with KRAS mutations.
In chapter 2, clinical studies with statins and other KRAS modulators and their use in cancer 
treatment are reviewed. This review indicates that combinations of EGFR antibodies to target the 
EGFR with KRAS modulators may be an effective approach in patients with KRAS mutant tumors.
Chapter 3 describes an in vitro study using KRAS wild type and mutant cell lines. The aim of this 
study was to understand the role of statins in CRC cells and to explore the potential of therapeutic 
modulation of KRAS mutated CRC tumor cell lines. Western blot analysis showed that simvastatin 
inhibited the prenylation of the KRAS protein. The inhibition by simvastatin resulted in less 
membrane association of KRAS. A survival assay was used to study the effects of simvastatin and 
cetuximab on proliferation in colorectal cancer cell lines. In KRAS G13D mutated HCT116 and LoVo 
cell lines a combination of simvastatin pre-treatment and cetuximab resulted in less proliferation. 
This effect was not observed in the SW480 cell line harbouring a codon 12 KRAS mutation. 
Since the in vitro studies showed promising results, we decided to perform a retrospective 
analysis to evaluate the effect of statin use on outcome in KRAS mutant metastatic CRC patients 
treated with cetuximab. In the CAIRO2 study by the Dutch Colorectal Study Group Metastatic 
CRC patients were treated with capecitabine, oxaliplatin, bevacizumab with or without cetuximab. 
We retrospectively analysed the effect of statin use at time of diagnosis on progression free 
survival (PFS) in CRC patients with KRAS mutant tumors treated with cetuximab and described 
the results in chapter 4. In our study we showed that the use of statins in patients with a KRAS 




In two prospective studies we investigated the potential of simvastatin to phenoconvert mutant 
KRAS in CRC patients treated with cetuximab or panitumumab. In the RASTAT C and P studies 
described in chapter 5 and 6, metastatic CRC patients who failed on first- and second-line therapy, 
were treated with 80 mg of simvastatin daily and cetuximab (RASTAT C) or panitumumab 
(RASTAT P). Both studies were terminated after a planned interim analysis of the Simon two-stage 
design, because similar survival as seen in KRAS wild type patients was not observed.
An important mechanism of cetuximab induced cell-killing is antibody-dependent cellular 
cytotoxicity (ADCC). Fc gamma receptors (FCGR) on effector cells, for example macrophages 
and natural killer cells, bind to the Fc fragment of the cetuximab molecule and this causes lysis of 
the cancer cell. The germline polymorphism (rs396991) in the Fc gamma receptor 3A (FCG3A) 
c.818A>C results in a change of phenylalanine to valine at codon 158. Previous results from 
studies investigating the association between F158V FCGR3A polymorphisms and cetuximab 
efficacy are highly variable and firm conclusions cannot be drawn. To clarify the effect of the 
FCGR3A F158V polymorphism on efficacy a meta-analysis was performed. The individual 
patient data meta-analysis (chapter 7) shows that FCGR3A polymorphism is not associated with 
improved survival in cetuximab treated CRC patients. Some earlier studies showed that patients 
with specific FCGR3A polymorphisms might benefit from cetuximab treatment regardless 
of their KRAS mutational status. In this study, there is no significant difference in cetuximab 
efficacy between patients with KRAS wild type and mutant tumors.
Both cetuximab and panitumumab are used in patients with advanced or metastatic 
disease. Due to previous treatment or metastatic disease these patient are likely to have renal 
or hepatic insufficiency. Knowledge of dosing in specials populations with impaired renal or 
hepatic function is highly relevant. The pharmacokinetics and safety of both cetuximab and 
panitumumab have not been studied in these special populations. In two case reports, with 
panitumumab and cetuximab in cancer patients with liver and kidney dysfunction respectively, 
we showed that dose adjustments in patients with liver or kidney failure are not necessary and 
that treatment seems to be tolerable and safe (chapters 8 and 9).
In chapter 10 the results from the performed research are discussed and future perspective 
are presented. Despite the promising results from the preclinical study, KRAS modulation with 
simvastatin is not applicable in the clinic and other strategies are needed for colorectal cancer 
patients with tumors harbouring a KRAS mutation who failed standard therapy. Besides statins, 
farnesyl- and geranylgeranyltransferase inhibitors also have a crucial role in the mevalonate 
pathway and consequently the prenylation of KRAS. A combination of statin and low doses 
farnesyl- and geranylgeranyltransferase inhibitors may be an effective treatment in CRC patients 
with a KRAS mutant tumor. Some studies reported that the effect of the FCGR3A polymorphisms 
on cetuximab efficacy is independent of KRAS status. The FCGR3A polymorphisms did not show 
a significant association with PFS. Moreover, no differences in cetuximab efficacy were found 
between patients with a KRAS mutant and KRAS wild type tumor. The results from these two 
approaches show that treatment options for CRC patients with a (K)RAS mutant tumor after 
failing chemotherapy and bevacizumab still remain poor. 
The described case reports in this thesis help clinical decision making in real-life practice. 
Cetuximab and panitumumab monotherapy seems to be safely applicable in patients with RAS 





In Nederland wordt jaarlijks bij circa 10.900 mensen dikkedarmkanker vastgesteld. De meest 
toegepaste behandelingen bij dikkedarmkanker zijn: een operatie, bestraling (radiotherapie) en 
behandeling met chemotherapie en antilichamen. Vaak is een combinatie van behandelmethoden 
nodig. Epidermale groei factor receptor (EGFR) antilichamen, zoals cetuximab en panitumumab 
zijn niet effectief gebleken bij de behandeling van patiënten met een KRAS mutante 
dikkedarmkanker. Ongeveer 40 % van de patiënten met een dikkedarmtumor heeft een mutatie 
in het KRAS gen. Indien behandeling met klassieke chemotherapie niet meer werkt zijn er 
voor deze patiëntengroep nog maar weinig behandelopties over. In dit promotieonderzoek is 
onderzoek gedaan naar drie verschillende manieren om de behandeling met EGFR-antilichamen 
te optimaliseren. Hierbij lag het accent op:
1. de effecten van statines bij de behandeling van dikkedarmtumoren met EGFR 
antilichamen;
2. de effecten van het FCGR3A polymorfisme en de effectiviteit van cetuximab;
3. de farmacokinetiek van cetuximab en panitumumab in patiënten met nier- of 
leverfunctiestoornissen. 
De KRAS mutatie in de tumor van deze patiëntengroep leidt tot een voortdurende productie van 
het KRAS eiwit en een continue activatie van de eiwitten: RAS, RAF en MAPK, zodat ‘upstream’ 
remming van de EGF-receptor geen zin heeft. Cholesterol verlagende statines remmen HMG-
CoA reductase en hierdoor de vorming van farnesylgroepen (C15-groepen) en geranyl-
geranylgroepen (C17- groepen). Deze twee groepen worden gebruikt om eiwitten, waaronder 
KRAS te prenyleren en te activeren. Bij de prenylatie worden aan het KRAS eiwit C15- of C17 
groepen gekoppeld. Door deze prenylatie wordt het KRAS eiwit lipofieler en verplaatst het zich 
naar het celmembraan, waar het zich verankert en zijn functie kan uitoefenen.
Statines en andere KRAS modulatoren, zoals bisfosfonaten en prenyltransferase remmers 
hebben mogelijk een effect op de expressie van het mutante KRAS eiwit omdat door een 
afgenomen prenylering minder KRAS eiwit geactiveerd wordt. (Deze fenotypische conversie 
leidt tot een meer wild type tumor en de hypothese is dat deze tumoren daardoor weer gevoelig 
worden voor de behandeling met EGFR-antilichamen.
In hoofdstuk 2 worden de behandeleffecten van statines en verschillende andere KRAS 
modulatoren bij patiënten met kanker beschreven. Dit overzicht laat zien dat combinatie van 
KRAS modulatoren en EGFR-antilichamen mogelijk effectief kan zijn bij patiënten met een 
KRAS mutante tumor.
In de preklinische “proof of concept” studie beschreven in hoofdstuk 3 wordt het effect van 
de combinatie van simvastatine en cetuximab onderzocht in vier verschillende KRAS mutante en 
wildtype tumor cellijnen. Het doel van deze studie was om te onderzoeken of deze tumor cellijnen 
door gelijktijdige behandeling met simvastatine weer gevoelig worden voor de behandeling met 
EGFR antilichamen. Met behulp van de Westernblot analyse werd aangetoond dat simvastatine 
de verplaatsting van KRAS eiwit van het cytoplasma naar het celmembraan remt. Het KRAS 
eiwit is hierdoor waarschijnlijk minder actief. In de KRAS G13D mutante cellijnen, LoVo en 
HCT 116, resulteerde combinatie behandeling met simvastatine en cetuximab in verminderde 
groei. Dit effect op de cel groei werd niet gezien in de KRAS wildtype cellijn A431 en de KRAS 




In een retrospectieve cohortanalyse van de CAIRO2 studie (hoofdstuk 4) is het effect 
van statinegebruik op de progressievrije overleving in de patiënten met KRAS mutante 
dikkedarmkanker behandeld met cetuximab onderzocht. Bij deze studie zijn alle in Nederland 
geregistreerde statines meegenomen. Statinegebruik leidde in deze patiëntengroep niet tot een 
betere progressievrije overleving ten opzichte van niet-statinegebruikers.
In twee multicenter klinische trials (hoofdstuk 5 en 6) zijn patiënten met een gemetastaseerd 
KRAS mutant colorectaal carcinoom in de derde lijn behandeld met dagelijks 80 mg simvastatine 
en daarnaast wekelijks cetuximab (RASTAT-C studie) of tweewekelijks panitumumab 
(RASTAT-P). De hypothese was dat de behandeling met de combinatie simvastatine met een 
EGFR- antilichaam een progressie vrije overleving geeft van 12.5 weken; deze overleving is gelijk 
aan de overleving die gezien wordt in KRAS wildtype patiënten. Deze studies werden opgezet 
volgens het Simon two-stage design. Dit betekent dat halverwege de studie, na inclusie van de 
helft van de benodigde patiënten een geplande interim analyse van het effect van de behandeling 
plaatsvindt. Bij een positief resultaat, mag de studie gecontinueerd worden en worden de 
overige patiënten geïncludeerd in de studie. Bij de geplande interim analyse van de RASTAT-C 
en RASTAT-P was de progressie vrije overleving bij patiënten behandeld met simvastatine en 
een EGFR-antilichaam niet gelijk aan de progressievrije overleving die gezien wordt in KRAS 
wildtype patiënten. Beide studies werden gestopt na de geplande interim analyse.
Antilichaam-afhankelijke cellulaire cytotoxiciteit (ADCC) zorgt er voor dat de kankercel door 
afweercellen, waaronder macrofagen, kapot gemaakt wordt. Dit wordt ook wel lysis genoemd. 
De Fc-gamma receptoren op macrofagen herkennen het Fc-fragment van het antilichaam en 
binden hieraan. Deze binding veroorzaakt lysis van de kankercel. Een belangrijk verondersteld 
werkingsmechanisme van cetuximab is ADCC en vervolgens lysis van de dikkedarmkankercel. 
Het kiembaan polymorfisme (rs396991) in het gen dat codeert voor de Fc-gamma receptor 3A 
(FCGR3A) zorgt er voor dat het aminozuur fenylalanine verandert in valine. Deze verandering 
van aminozuur veroorzaakt mogelijk veranderingen in de affiniteit van de FCGR3A voor het 
EGFR antilichaam cetuximab. Verschillende studies hebben gekeken naar het effect van het 
polymorfisme op de effectiviteit van cetuximab. De uitkomsten waren echter zeer variabel en 
dit leidde niet tot duidelijke conclusies. Met behulp van een individuele patiëntendata meta-
analyse (hoofdstuk 7) werd gekeken naar het effect van het FCGR3A polymorfisme en cetuximab 
effectiviteit in patiënten met KRAS mutante en wild type dikkedarmtumoren. Het FCGR3A 
polymorfisme had geen invloed op de progressievrije overleving van patiënten met een KRAS 
mutante dikkedarm tumor. 
Cetuximab en panitumumab worden beiden toegepast bij patiënten met vergevorderde 
of gemetastaseerde ziekte. Door een uitgebreide voorbehandeling met bijvoorbeeld 
chemotherapie of gemetastaseerde ziekte presenteert een deel van deze patiënten zich met 
nier- en leverfunctiestoornissen. De toepassing van panitumumab en cetuximab is echter alleen 
onderzocht bij patiënten met een goede nier- of leverfunctie. Deze twee case reports (hoofdstuk 
8 en 9) laten zien dat de farmacokinetiek van cetuximab en panitumumab in patiënten met nier- 
of leverfunctiestoornissen niet verschilt van patiënten zonder nier- of leverfunctiestoornissen. 
Dosis verlaging is niet noodzakelijk en de behandeling lijkt veilig.
Tot slot worden in hoofdstuk 10 de resultaten van het gehele onderzoek in dit proefschrift 
bediscussieerd en wordt een toekomstperspectief voor verder onderzoek geschetst. Ondanks 
de aanwijzingen vanuit het preklinisch in vitro onderzoek dat statines, KRAS mutante 
dikkedarmkanker cellen gevoelig kunnen maken voor EGFR antilichamen leidde het gebruik 
van statines in de prospectieve studies en de cohortanalyse echter niet tot een verbeterde 
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progressie vrije overleving. Daarnaast was de effectiviteit van cetuximab niet verschillend voor 
de verschillende FCGR3A polymorfismen. De behandelingsmogelijkheden van patiënten met 
een KRAS mutante tumor blijven uiterst beperkt en andere therapieën zijn nodig om patiënten 
met een KRAS mutante dikkedarmtumor te behandelen. 
De bijwerking van huidtoxiciteit voorkomen is belangrijk om het effect van de EGFR-anti-
lichamen te maximaliseren. De identificatie van SNPs geassocieerd met huidtoxiciteit dragen 
mogelijk bij aan een verdere optimalisatie en nieuwe inzichten van de therapie met EGFR-
antilichamen.
Tenslotte laten de gepresenteerde case reports zien dat dosisaanpassingen niet noodzakelijk 
zijn bij lever- en nierfunctiestoornissen. Dit zal echter in de toekomst in grotere patiëntenstudies 
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Jan, door jouw altijd positieve instelling en creatieve oplossingen kon ik vaak weer verder, ook uit 
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fase heb ik als erg waardevol ervaren. Renee, dank voor alle hulp, ondersteuning en gezelligheid 
gedurende de lab experimenten. 
Jara, we zijn samen gestart aan onze promotie. Het was leerzaam en motiverend om de klinische 
kant en de farmaceutische kant van het onderzoek met monoklonale EGFR-antilichamen op 
deze manier te verbinden. 
Ik bedank alle co-auteurs, voor hun waardevolle input bij het uitvoeren, afronden en opschrijven 
van de verschillende onderzoeken uitgevoerd in het kader van dit promotietraject.
Ik wil graag mijn kamergenoten (AIOS en promovendi) door de jaren heen bedanken. Een goed 
gesprek, wat afleiding of het sparren over statistiek zorgt uiteindelijk dat je verder komt.
Graag wil ik alle (oud)collega’s van de apotheek van het LUMC bedanken. Ik ben dankbaar voor 
jullie interesse en positieve bijdrage tijdens zowel mijn opleiding tot ziekenhuisapotheker als 
gedurende mijn promotie onderzoek.
De laatste loodjes zijn zwaar en in het laatste jaar van mijn promotie onderzoek is er veel 
veranderd. Beste (nieuwe) collega’s uit de ZGT, fijn dat jullie zo betrokken zijn. Dankjewel voor 
jullie interesse en ondersteuning gedurende de afronding van mijn proefschrift.
Beste paranimfen, Stefanie en Eline, dank voor jullie steun gedurende mijn promotie traject. 
Stefanie, het is altijd erg prettig om met jou te discussiëren over onderzoek doen en de 
ziekenhuisfarmacie. Eline, dankjewel voor de belangstelling en gezelligheid de afgelopen jaren. 
Lieve ouders en schoonouders, dank voor jullie interesse in mijn onderzoek, gezelligheid en 
wijze woorden.
Tot slot, lieve Lukas, dankjewel voor je steun, goede discussies over zeer uiteenlopende 
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